Search

Your search keyword '"Zongyi W"' showing total 40 results
Start Over Author "Zongyi W" Search Limiters Full Text
40 results on '"Zongyi W"'

1. Application of gelatin-based composites in bone tissue engineering

Author

Enguang Wu, Lianghui Huang, Yao Shen, Zongyi Wei, Yangbiao Li, Jin Wang, and Zhenhua Chen

Subjects
Gelatin, Composite materials, Bone tissue engineering, Bone repair, Science (General), Q1-390, Social sciences (General), H1-99
Abstract

Natural bone tissue has the certain function of self-regeneration and repair, but it is difficult to repair large bone damage. Recently, although autologous bone grafting is the “gold standard” for improving bone repair, it has high cost, few donor sources. Besides, allogeneic bone grafting causes greater immune reactions, which hardly meet clinical needs. The bone tissue engineering (BTE) has been developed to promote bone repair. Gelatin, due to its biocompatibility, receives a great deal of attention in the BTE research field. However, the disadvantages of natural gelatin are poor mechanical properties and single structural property. With the development of BTE, gelatin is often used in combination with a range of natural, synthetic polymers, and inorganic materials to achieve synergistic effects for the complex physiological process of bone repair. The review delves into the fundamental structure and unique properties of gelatin, as well as the excellent properties necessary for bone scaffold materials. Then this review explores the application of modified gelatin three-dimensional (3D) scaffolds with various structures in bone repair, including 3D fiber scaffolds, hydrogels, and nanoparticles. In addition, the review focuses on the excellent efficacy of composite bone tissue scaffolds consisting of modified gelatin, various natural or synthetic polymeric materials, as well as bioactive ceramics and inorganic metallic/non-metallic materials in the repair of bone defects. The combination of these gelatin-based composite scaffolds provides new ideas for the design of scaffold materials for bone repair with good biosafety.

Published
2024
Full Text
View/download PDF

2. Sevoflurane postconditioning ameliorates cerebral hypoxia/reoxygenation injury in zebrafish involving the Akt/GSK-3β pathway activation and the microtubule-associated protein 2 promotion

Author

Li Zhang, Mengsi Yang, Zongyi Wang, Dinggang Fan, Fang Shen, Xuezhu Zou, Xiaoyuan Zhang, Su Hu, Bing Hu, and Xianwen Hu

Subjects
Sevoflurane postconditioning, Cerebral hypoxia/reoxygenation injury, Cerebral protection, MAP2, Zebrafish, Therapeutics. Pharmacology, RM1-950
Abstract

Sevoflurane postconditioning has been shown to provide neuroprotection against cerebral hypoxia-ischemia injury, but the mechanisms remain elusive. Microtubule-associated protein 2 (MAP2) is implicated in early neuronal hypoxia-ischemia injury. This study aimed to investigate whether the neuroprotective effects of sevoflurane postconditioning are related to the Akt/GSK-3β pathway and its downstream target MAP2 in zebrafish hypoxia/reoxygenation (H/R) model. Sevoflurane postconditioning or GSK-3β inhibitor TDZD-8 were used to treat H/R zebrafish. The cerebral infarction, neuronal apoptosis, and mitochondrial changes were evaluated using TTC staining, TUNEL staining, and transmission electron microscopy, respectively. The distribution of MAP2 in the brain was determined by immunofluorescence imaging. The levels of Akt, p-Akt, GSK-3β, p-GSK-3β, and MAP2 proteins were evaluated by Western blotting. The neurobehavioral recovery of zebrafish was assessed based on optokinetic response behavior. Our results indicated that sevoflurane postconditioning and TDZD-8 significantly reduced the cerebral infarction area, suppressed cell apoptosis, and improved mitochondrial integrity in zebrafish subjected to H/R. Furthermore, sevoflurane postconditioning and TDZD-8 elevated the ratios of p-Akt/Akt and p-GSK-3β/GSK-3β. However, the neuroprotective effect of sevoflurane postconditioning was effectively abolished upon suppression of MAP2 expression. In conclusion, sevoflurane postconditioning ameliorated cerebral H/R injury and facilitated the restoration of neurobehavioral function through the activation of Akt/GSK-3β pathway and promotion of MAP2 expression.

Published
2024
Full Text
View/download PDF

3. Repositioning fertilizer manufacturing subsidies for improving food security and reducing greenhouse gas emissions in China

Author

Zongyi Wu, Xiaolong Feng, Yumei Zhang, and Shenggen Fan

Subjects
food security, fertilizer manufacturing subsidies, agri-food systems, greenhouse gas emissions, Agriculture (General), S1-972
Abstract

China removed fertilizer manufacturing subsidies from 2015 to 2018 to bolster market-oriented reforms and foster environmentally sustainable practices. However, the impact of this policy reform on food security and the environment remains inadequately evaluated. Moreover, although green and low-carbon technologies offer environmental advantages, their widespread adoption is hindered by prohibitively high costs. This study analyzes the impact of removing fertilizer manufacturing subsidies and explores the potential feasibility of redirecting fertilizer manufacturing subsidies to invest in the diffusion of these technologies. Utilizing the China Agricultural University Agri-food Systems model, we analyzed the potential for achieving mutually beneficial outcomes regarding food security and environmental sustainability. The findings indicate that removing fertilizer manufacturing subsidies has reduced greenhouse gas (GHG) emissions from agricultural activities by 3.88 million metric tons, with minimal impact on food production. Redirecting fertilizer manufacturing subsidies to invest in green and low-carbon technologies, including slow and controlled-release fertilizer, organic–inorganic compound fertilizers, and machine deep placement of fertilizer, emerges as a strategy to concurrently curtail GHG emissions, ensure food security, and secure robust economic returns. Finally, we propose a comprehensive set of government interventions, including subsidies, field guidance, and improved extension systems, to promote the widespread adoption of these technologies.

Published
2024
Full Text
View/download PDF

4. Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes

Author

Zongyi Wu, Wei Deng, Yiming Ye, Jie Xu, Deyu Han, Yu Zheng, and Qun Zheng

Subjects
liraglutide, osteoporosis, diabetes, efficacy, possible mechanisms, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

IntroductionLiraglutide (Lrg), a novel anti-diabetic drug that mimics the endogenous glucagon-like peptide-1 to potentiate insulin secretion, is observed to be capable of partially reversing osteopenia. The aim of the present study is to further investigate the efficacy and potential anti-osteoporosis mechanisms of Lrg for improving bone pathology, bone- related parameters under imageology, and serum bone metabolism indexes in an animal model of osteoporosis with or without diabetes. MethodsEight databases were searched from their inception dates to April 27, 2024. The risk of bias and data on outcome measures were analyzed by the CAMARADES 10-item checklist and Rev-Man 5.3 software separately.ResultsSeventeen eligible studies were ultimately included in this review. The number of criteria met in each study varied from 4/10 to 8/10 with an average of 5.47. The aspects of blinded induction of the model, blinding assessment of outcome and sample size calculation need to be strengthened with emphasis. The pre-clinical evidence reveals that Lrg is capable of partially improving bone related parameters under imageology, bone pathology, and bone maximum load, increasing serum osteocalcin, N-terminal propeptide of type I procollagen, and reducing serum c-terminal cross-linked telopeptide of type I collagen (P

Published
2024
Full Text
View/download PDF

5. Magnetic-driven hydrogel microrobots for promoting osteosarcoma chemo-therapy with synthetic lethality strategy

Author

Yining Tao, Leike Li, Xiyu Yang, Shiyu Yin, Zhanxiang Zhang, Haoyu Wang, Ruochen Pu, Zongyi Wang, Qi Zhang, Haoran Mu, Chenqiong Wu, Jin He, and Liu Yang

Subjects
microrobots, magnetic-driven, drug delivery system, MYC, synthetic lethality, osteosarcoma, Chemistry, QD1-999
Abstract

The advancements in the field of micro-robots for drug delivery systems have garnered considerable attention. In contrast to traditional drug delivery systems, which are dependent on blood circulation to reach their target, these engineered micro/nano robots possess the unique ability to navigate autonomously, thereby enabling the delivery of drugs to otherwise inaccessible regions. Precise drug delivery systems can improve the effectiveness and safety of synthetic lethality strategies, which are used for targeted therapy of solid tumors. MYC-overexpressing tumors show sensitivity to CDK1 inhibition. This study delves into the potential of Ro-3306 loaded magnetic-driven hydrogel micro-robots in the treatment of MYC-dependent osteosarcoma. Ro-3306, a specific inhibitor of CDK1, has been demonstrated to suppress tumor growth across various types of cancer. We have designed and fabricated this micro-robot, capable of delivering Ro-3306 precisely to tumor cells under the influence of a magnetic field, and evaluated its chemosensitizing effects, thereby augmenting the therapeutic efficacy and introducing a novel possibility for osteosarcoma treatment. The clinical translation of this method necessitates further investigation and validation. In summary, the Ro-3306-loaded magnetic-driven hydrogel micro-robots present a novel strategy for enhancing the chemosensitivity of MYC-dependent osteosarcoma, paving the way for new possibilities in future clinical applications.

Published
2024
Full Text
View/download PDF

7. Multi-objective optimal scheduling considering low-carbon operation of air conditioner load with dynamic carbon emission factors

Author

Xin Shen, Jiahao Li, Yujun Yin, Jianlin Tang, Bin Qian, Xiaoming Lin, and Zongyi Wang

Subjects
low-carbon operation, economic scheduling, air conditioning system, multiobjective optimization, dynamic carbon emission factor, General Works
Abstract

As global temperatures rise and climate change becomes more severely. People realize that air conditioning systems as a controllable resource and play an increasingly important role in reducing carbon emissions. In the past, the operation optimization of air conditioning systems was mainly oriented to user comfort and electricity costs ignoring the long-term impact on the environment. This article aims to establish a multi-objective model of air-conditioning load to ensure user temperature comfort performance and reduce the total cost (i.e., electricity cost and carbon emission cost) simultaneously. Multi Sand Cat Swarm Optimization (MSCSO) algorithm combined with gray target decision-making (GTD) is used to explore optimal solution. Meanwhile four competitive strategies are applied to validate the effectiveness of the proposed method, i.e., genetic algorithm (GA), MSCSO-comfort objective, MSCSO-total electricity cost objective and unoptimization. The simulation results show that the MSCSO-GTD based objective method can significantly reduce total costs while taking into account appropriate indoor temperature comfort.

Published
2024
Full Text
View/download PDF

8. Elevated number and density of macrophage-like cell as a novel inflammation biomarker in diabetic macular edema

Author

Zongyi Wang, Haiyan An, Jiyang Tang, Enzhong Jin, Siying Li, Linqi Zhang, Lvzhen Huang, and Jinfeng Qu

Subjects
Medicine, Science
Abstract

Abstract To quantitatively analyze the number and density of macrophage-like cells (MLCs) at the vitreoretinal interface at macular region in diabetic retinopathy (DR) with and without diabetic macular edema (DME). This cross-sectional study involved 240 eyes of 146 treatment-naïve DR patients, including 151 eyes with DME. The number and density of MLCs were analyzed quantitatively using optical coherence tomography angiography (OCTA) and were compared between DME and non-DME eyes as well as proliferative DR (PDR) and non-PDR (NPDR) eyes. Correlation between MLCs density and vessel density of macular superficial capillary plexus (SCP) at macular region was evaluated. The number and density of macular MLCs were both elevated in DME group compared to non-DME group (all p

Published
2023
Full Text
View/download PDF

9. Mass testing and characterization of 20-inch PMTs for JUNO

Author

Angel Abusleme, Thomas Adam, Shakeel Ahmad, Rizwan Ahmed, Sebastiano Aiello, Muhammad Akram, Abid Aleem, Tsagkarakis Alexandros, Fengpeng An, Qi An, Giuseppe Andronico, Nikolay Anfimov, Vito Antonelli, Tatiana Antoshkina, Burin Asavapibhop, João Pedro Athayde Marcondes de André, Didier Auguste, Weidong Bai, Nikita Balashov, Wander Baldini, Andrea Barresi, Davide Basilico, Eric Baussan, Marco Bellato, Antonio Bergnoli, Thilo Birkenfeld, Sylvie Blin, David Blum, Simon Blyth, Anastasia Bolshakova, Mathieu Bongrand, Clément Bordereau, Dominique Breton, Augusto Brigatti, Riccardo Brugnera, Riccardo Bruno, Antonio Budano, Jose Busto, Ilya Butorov, Anatael Cabrera, Barbara Caccianiga, Hao Cai, Xiao Cai, Yanke Cai, Zhiyan Cai, Riccardo Callegari, Antonio Cammi, Agustin Campeny, Chuanya Cao, Guofu Cao, Jun Cao, Rossella Caruso, Cédric Cerna, Chi Chan, Jinfan Chang, Yun Chang, Guoming Chen, Pingping Chen, Po-An Chen, Shaomin Chen, Xurong Chen, Yixue Chen, Yu Chen, Zhiyuan Chen, Zikang Chen, Jie Cheng, Yaping Cheng, Yu Chin Cheng, Alexey Chetverikov, Davide Chiesa, Pietro Chimenti, Artem Chukanov, Gérard Claverie, Catia Clementi, Barbara Clerbaux, Marta Colomer Molla, Selma Conforti Di Lorenzo, Daniele Corti, Flavio Dal Corso, Olivia Dalager, Christophe De La Taille, Zhi Deng, Ziyan Deng, Wilfried Depnering, Marco Diaz, Xuefeng Ding, Yayun Ding, Bayu Dirgantara, Sergey Dmitrievsky, Tadeas Dohnal, Dmitry Dolzhikov, Georgy Donchenko, Jianmeng Dong, Evgeny Doroshkevich, Marcos Dracos, Frédéric Druillole, Ran Du, Shuxian Du, Stefano Dusini, Martin Dvorak, Timo Enqvist, Heike Enzmann, Andrea Fabbri, Donghua Fan, Lei Fan, Jian Fang, Wenxing Fang, Marco Fargetta, Dmitry Fedoseev, Zhengyong Fei, Li-Cheng Feng, Qichun Feng, Richard Ford, Amélie Fournier, Haonan Gan, Feng Gao, Alberto Garfagnini, Arsenii Gavrikov, Marco Giammarchi, Nunzio Giudice, Maxim Gonchar, Guanghua Gong, Hui Gong, Yuri Gornushkin, Alexandre Göttel, Marco Grassi, Vasily Gromov, Minghao Gu, Xiaofei Gu, Yu Gu, Mengyun Guan, Yuduo Guan, Nunzio Guardone, Cong Guo, Jingyuan Guo, Wanlei Guo, Xinheng Guo, Yuhang Guo, Paul Hackspacher, Caren Hagner, Ran Han, Yang Han, Miao He, Wei He, Tobias Heinz, Patrick Hellmuth, Yuekun Heng, Rafael Herrera, YuenKeung Hor, Shaojing Hou, Yee Hsiung, Bei-Zhen Hu, Hang Hu, Jianrun Hu, Jun Hu, Shouyang Hu, Tao Hu, Yuxiang Hu, Zhuojun Hu, Guihong Huang, Hanxiong Huang, Kaixuan Huang, Wenhao Huang, Xin Huang, Xingtao Huang, Yongbo Huang, Jiaqi Hui, Lei Huo, Wenju Huo, Cédric Huss, Safeer Hussain, Ara Ioannisian, Roberto Isocrate, Beatrice Jelmini, Ignacio Jeria, Xiaolu Ji, Huihui Jia, Junji Jia, Siyu Jian, Di Jiang, Wei Jiang, Xiaoshan Jiang, Xiaoping Jing, Cécile Jollet, Jari Joutsenvaara, Leonidas Kalousis, Philipp Kampmann, Li Kang, Rebin Karaparambil, Narine Kazarian, Amina Khatun, Khanchai Khosonthongkee, Denis Korablev, Konstantin Kouzakov, Alexey Krasnoperov, Nikolay Kutovskiy, Pasi Kuusiniemi, Tobias Lachenmaier, Cecilia Landini, Sébastien Leblanc, Victor Lebrin, Frederic Lefevre, Ruiting Lei, Rupert Leitner, Jason Leung, Daozheng Li, Demin Li, Fei Li, Fule Li, Gaosong Li, Huiling Li, Mengzhao Li, Min Li, Nan Li, Qingjiang Li, Ruhui Li, Rui Li, Shanfeng Li, Tao Li, Teng Li, Weidong Li, Weiguo Li, Xiaomei Li, Xiaonan Li, Xinglong Li, Yi Li, Yichen Li, Yufeng Li, Zepeng Li, Zhaohan Li, Zhibing Li, Ziyuan Li, Zonghai Li, Hao Liang, Jiajun Liao, Ayut Limphirat, Guey-Lin Lin, Shengxin Lin, Tao Lin, Jiajie Ling, Ivano Lippi, Fang Liu, Haidong Liu, Haotian Liu, Hongbang Liu, Hongjuan Liu, Hongtao Liu, Hui Liu, Jianglai Liu, Jinchang Liu, Min Liu, Qian Liu, Qin Liu, Runxuan Liu, Shubin Liu, Shulin Liu, Xiaowei Liu, Xiwen Liu, Yan Liu, Yunzhe Liu, Alexey Lokhov, Paolo Lombardi, Claudio Lombardo, Kai Loo, Chuan Lu, Haoqi Lu, Jingbin Lu, Junguang Lu, Shuxiang Lu, Bayarto Lubsandorzhiev, Sultim Lubsandorzhiev, Livia Ludhova, Arslan Lukanov, Daibin Luo, Fengjiao Luo, Guang Luo, Shu Luo, Wuming Luo, Xiaojie Luo, Vladimir Lyashuk, Bangzheng Ma, Bing Ma, Qiumei Ma, Si Ma, Xiaoyan Ma, Xubo Ma, Jihane Maalmi, Jingyu Mai, Yury Malyshkin, Roberto Carlos Mandujano, Fabio Mantovani, Francesco Manzali, Xin Mao, Yajun Mao, Stefano M. Mari, Filippo Marini, Cristina Martellini, Gisele Martin-Chassard, Agnese Martini, Matthias Mayer, Davit Mayilyan, Ints Mednieks, Yue Meng, Anselmo Meregaglia, Emanuela Meroni, David Meyhöfer, Mauro Mezzetto, Jonathan Miller, Lino Miramonti, Paolo Montini, Michele Montuschi, Axel Müller, Massimiliano Nastasi, Dmitry V. Naumov, Elena Naumova, Diana Navas-Nicolas, Igor Nemchenok, Minh Thuan Nguyen Thi, Feipeng Ning, Zhe Ning, Hiroshi Nunokawa, Lothar Oberauer, Juan Pedro Ochoa-Ricoux, Alexander Olshevskiy, Domizia Orestano, Fausto Ortica, Rainer Othegraven, Alessandro Paoloni, Sergio Parmeggiano, Yatian Pei, Luca Pelicci, Nicomede Pelliccia, Anguo Peng, Haiping Peng, Yu Peng, Zhaoyuan Peng, Frédéric Perrot, Pierre-Alexandre Petitjean, Fabrizio Petrucci, Oliver Pilarczyk, Luis Felipe Piñeres Rico, Artyom Popov, Pascal Poussot, Ezio Previtali, Fazhi Qi, Ming Qi, Sen Qian, Xiaohui Qian, Zhen Qian, Hao Qiao, Zhonghua Qin, Shoukang Qiu, Gioacchino Ranucci, Neill Raper, Alessandra Re, Henning Rebber, Abdel Rebii, Mariia Redchuk, Bin Ren, Jie Ren, Barbara Ricci, Mariam Rifai, Mathieu Roche, Narongkiat Rodphai, Aldo Romani, Bedřich Roskovec, Xichao Ruan, Arseniy Rybnikov, Andrey Sadovsky, Paolo Saggese, Simone Sanfilippo, Anut Sangka, Utane Sawangwit, Julia Sawatzki, Michaela Schever, Cédric Schwab, Konstantin Schweizer, Alexandr Selyunin, Andrea Serafini, Giulio Settanta, Mariangela Settimo, Zhuang Shao, Vladislav Sharov, Arina Shaydurova, Jingyan Shi, Yanan Shi, Vitaly Shutov, Andrey Sidorenkov, Fedor Šimkovic, Chiara Sirignano, Jaruchit Siripak, Monica Sisti, Maciej Slupecki, Mikhail Smirnov, Oleg Smirnov, Thiago Sogo-Bezerra, Sergey Sokolov, Julanan Songwadhana, Boonrucksar Soonthornthum, Albert Sotnikov, Ondřej Šrámek, Warintorn Sreethawong, Achim Stahl, Luca Stanco, Konstantin Stankevich, Dušan Štefánik, Hans Steiger, Jochen Steinmann, Tobias Sterr, Matthias Raphael Stock, Virginia Strati, Alexander Studenikin, Jun Su, Shifeng Sun, Xilei Sun, Yongjie Sun, Yongzhao Sun, Zhengyang Sun, Narumon Suwonjandee, Michal Szelezniak, Jian Tang, Qiang Tang, Quan Tang, Xiao Tang, Eric Theisen, Alexander Tietzsch, Igor Tkachev, Tomas Tmej, Marco Danilo Claudio Torri, Konstantin Treskov, Andrea Triossi, Giancarlo Troni, Wladyslaw Trzaska, Cristina Tuve, Nikita Ushakov, Vadim Vedin, Giuseppe Verde, Maxim Vialkov, Benoit Viaud, Cornelius Moritz Vollbrecht, Cristina Volpe, Katharina von Sturm, Vit Vorobel, Dmitriy Voronin, Lucia Votano, Pablo Walker, Caishen Wang, Chung-Hsiang Wang, En Wang, Guoli Wang, Jian Wang, Jun Wang, Lu Wang, Meifen Wang, Meng Wang, Ruiguang Wang, Siguang Wang, Wei Wang, Wenshuai Wang, Xi Wang, Xiangyue Wang, Yangfu Wang, Yaoguang Wang, Yi Wang, Yifang Wang, Yuanqing Wang, Yuman Wang, Zhe Wang, Zheng Wang, Zhimin Wang, Zongyi Wang, Apimook Watcharangkool, Wei Wei, Wenlu Wei, Yadong Wei, Kaile Wen, Liangjian Wen, Christopher Wiebusch, Steven Chan-Fai Wong, Bjoern Wonsak, Diru Wu, Qun Wu, Zhi Wu, Michael Wurm, Jacques Wurtz, Christian Wysotzki, Yufei Xi, Dongmei Xia, Xiang Xiao, Xiaochuan Xie, Yuguang Xie, Zhangquan Xie, Zhao Xin, Zhizhong Xing, Benda Xu, Cheng Xu, Donglian Xu, Fanrong Xu, Hangkun Xu, Jilei Xu, Jing Xu, Meihang Xu, Yin Xu, Yu Xu, Baojun Yan, Taylor Yan, Wenqi Yan, Xiongbo Yan, Yupeng Yan, Changgen Yang, Chengfeng Yang, Huan Yang, Jie Yang, Lei Yang, Xiaoyu Yang, Yifan Yang, Haifeng Yao, Jiaxuan Ye, Mei Ye, Ziping Ye, Frédéric Yermia, Na Yin, Zhengyun You, Boxiang Yu, Chiye Yu, Chunxu Yu, Hongzhao Yu, Miao Yu, Xianghui Yu, Zeyuan Yu, Zezhong Yu, Cenxi Yuan, Chengzhuo Yuan, Ying Yuan, Zhenxiong Yuan, Baobiao Yue, Noman Zafar, Vitalii Zavadskyi, Shan Zeng, Tingxuan Zeng, Yuda Zeng, Liang Zhan, Aiqiang Zhang, Bin Zhang, Binting Zhang, Feiyang Zhang, Guoqing Zhang, Honghao Zhang, Jialiang Zhang, Jiawen Zhang, Jie Zhang, Jin Zhang, Jingbo Zhang, Jinnan Zhang, Mohan Zhang, Peng Zhang, Qingmin Zhang, Shiqi Zhang, Shu Zhang, Tao Zhang, Xiaomei Zhang, Xin Zhang, Xuantong Zhang, Xueyao Zhang, Yinhong Zhang, Yiyu Zhang, Yongpeng Zhang, Yu Zhang, Yuanyuan Zhang, Yumei Zhang, Zhenyu Zhang, Zhijian Zhang, Fengyi Zhao, Jie Zhao, Rong Zhao, Runze Zhao, Shujun Zhao, Dongqin Zheng, Hua Zheng, Yangheng Zheng, Weirong Zhong, Jing Zhou, Li Zhou, Nan Zhou, Shun Zhou, Tong Zhou, Xiang Zhou, Jiang Zhu, Jingsen Zhu, Kangfu Zhu, Kejun Zhu, Zhihang Zhu, Bo Zhuang, Honglin Zhuang, Liang Zong, Jiaheng Zou, and JUNO Collaboration

Subjects
Astrophysics, QB460-466, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Abstract Main goal of the JUNO experiment is to determine the neutrino mass ordering using a 20 kt liquid-scintillator detector. Its key feature is an excellent energy resolution of at least 3% at 1 MeV, for which its instruments need to meet a certain quality and thus have to be fully characterized. More than 20,000 20-inch PMTs have been received and assessed by JUNO after a detailed testing program which began in 2017 and elapsed for about four years. Based on this mass characterization and a set of specific requirements, a good quality of all accepted PMTs could be ascertained. This paper presents the performed testing procedure with the designed testing systems as well as the statistical characteristics of all 20-inch PMTs intended to be used in the JUNO experiment, covering more than fifteen performance parameters including the photocathode uniformity. This constitutes the largest sample of 20-inch PMTs ever produced and studied in detail to date, i.e. 15,000 of the newly developed 20-inch MCP-PMTs from Northern Night Vision Technology Co. (NNVT) and 5000 of dynode PMTs from Hamamatsu Photonics K. K.(HPK).

Published
2022
Full Text
View/download PDF

10. Wolfram syndrome 1b mutation suppresses Mauthner-cell axon regeneration via ER stress signal pathway

Author

Zongyi Wang, Xinliang Wang, Lingyu Shi, Yuan Cai, and Bing Hu

Subjects
wfs1b, Zebrafish, Mauthner cell, ER stress, Regeneration, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Wolfram Syndrome (WS) is a fatal human inherited disease with symptoms of diabetes, vision decreasing, and neurodegeneration caused by mutations in the endoplasmic reticulum (ER)-resident protein WFS1. WFS1 has been reported to play an important role in glucose metabolism. However, the role of WFS1 in axonal regeneration in the central nervous system has so far remained elusive. Herein, we established a model of the wfs1b globally deficient zebrafish line. wfs1b deficiency severely impeded the Mauthner-cell (M-cell) axon regeneration, which was partly dependent on the ER stress response. The administration of ER stress inhibitor 4-Phenylbutyric acid (4-PBA) promoted M-cell axon regeneration in wfs1b −/− zebrafish larvae, while the ER stress activator Tunicamycin (TM) inhibited M-cell axon regeneration in wfs1b +/+ zebrafish larvae. Moreover, complementation of wfs1b at the single-cell level stimulated M-cell axon regeneration in the wfs1b −/− zebrafish larvae. Altogether, our results revealed that wfs1b promotes M-cell axon regeneration through the ER stress signal pathway and provide new evidence for a therapeutic target for WS and axon degeneration.

Published
2022
Full Text
View/download PDF

11. Correlation of photoreceptor damage with anti-retina antibodies level in aqueous humor in macular edema patients

Author

Xinyao Han, Linqi Zhang, Jiyang Tang, Zongyi Wang, Siying Li, Li Yuan, and Jinfeng Qu

Subjects
Medicine, Science
Abstract

Abstract This study aimed to investigate the correlation between the severity of photoreceptor damage and the level of anti-retina antibodies (ARAs) in aqueous humor, including recoverin, CA II and enolase-α IgG antibody of macular edema patients. Aqueous humor samples were collected from macular edema patients and from cataract patients. Patients were divided into three groups according to the severity of discontinuity of ellipsoid zone (EZ) shown on optical coherence tomography (OCT) imaging: cataract patients with intact EZ, macular edema patients with mild EZ damage, and macular edema patients with severe EZ damage. The level of ARAs was determined with enzyme-linked immunosorbent assay (ELISA). The correlation between the level of ARAs and the degree of photoreceptor damage was analyzed. The level of ARAs of the intact EZ group was significantly lower than that in the severely damaged group (P

Published
2022
Full Text
View/download PDF

12. Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial

Author

Siying Li, Lili Guo, Pingping Zhou, Jiyang Tang, Zongyi Wang, Linqi Zhang, Mingwei Zhao, and Jinfeng Qu

Subjects
Proliferative diabetic retinopathy, Anti-VEGF, Ranibizumab, Conbercept, Preoperative intravitreal injections, Diabetic vitrectomy, Ophthalmology, RE1-994
Abstract

Abstract Background To compare the efficacy and safety of preoperative intravitreal injections of ranibizumab and conbercept in Chinese proliferative diabetic retinopathy (PDR) patients. Methods This prospective randomized controlled trial enrolled 90 eyes of 80 patients with PDR. Forty-four eyes of 40 patients that received intravitreal ranibizumab (IVR) injections (0.5 mg/0.05 mL) before vitreous surgeries were assigned to the IVR group. Forty-six eyes of 40 patients that received intravitreal conbercept (IVC) injections (0.5 mg/0.05 mL) before vitreous surgeries were assigned to the IVC group. Intraoperative and postoperative indices were assessed for further comparison between the two groups. Results There were no statistically significant differences in all surgery indices, including intraoperative indices (surgery time, P = 0.225; intraoperative bleeding, P = 0.808; endodiathermy use, P = 0.693; incidence of iatrogenic retinal breaks, P = 0.740; relaxing retinotomy, P = 0.682; retinal reattachment, P = 0.682 and silicone oil tamponade, P = 0.814) and postoperative indices (postoperative vitreous hemorrhage (VH), P = 0.808; neovascular glaucoma (NVG), P = 0.964; recurrent retinal detachment, P = 0.531; postoperative fibrovascular proliferation progression, P = 0.682 and reoperation, P = 0.955) between the two groups. There were no statistically significant differences in best-corrected visual acuity (BCVA) at each follow-up visit (P = 0.939, 0.669, 0.741 and 0.717, respectively) or in central retinal thickness (CRT) (P = 0.976, 0.699, 0.551 and 0.686, respectively). As for safety profile, both groups had no ocular or system adverse events during the observation period. Conclusions IVR and IVC as a pretreatment of vitrectomy had similar efficacy and safety profile for Chinese PDR patients. Trial registration: Registered at ClinicalTrials.gov ( NCT05414149 ).

Published
2022
Full Text
View/download PDF

13. Model-independent Approach of the JUNO 8B Solar Neutrino Program

Author

Jie Zhao, Baobiao Yue, Haoqi Lu, Yufeng Li, Jiajie Ling, Zeyuan Yu, Angel Abusleme, Thomas Adam, Shakeel Ahmad, Rizwan Ahmed, Sebastiano Aiello, Muhammad Akram, Abid Aleem, Tsagkarakis Alexandros, Fengpeng An, Qi An, Giuseppe Andronico, Nikolay Anfimov, Vito Antonelli, Tatiana Antoshkina, Burin Asavapibhop, João Pedro Athayde Marcondes de André, Didier Auguste, Weidong Bai, Nikita Balashov, Wander Baldini, Andrea Barresi, Davide Basilico, Eric Baussan, Marco Bellato, Antonio Bergnoli, Thilo Birkenfeld, Sylvie Blin, David Blum, Simon Blyth, Anastasia Bolshakova, Mathieu Bongrand, Clément Bordereau, Dominique Breton, Augusto Brigatti, Riccardo Brugnera, Riccardo Bruno, Antonio Budano, Jose Busto, Ilya Butorov, Anatael Cabrera, Barbara Caccianiga, Hao Cai, Xiao Cai, Yanke Cai, Zhiyan Cai, Riccardo Callegari, Antonio Cammi, Agustin Campeny, Chuanya Cao, Guofu Cao, Jun Cao, Rossella Caruso, Cédric Cerna, Chi Chan, Jinfan Chang, Yun Chang, Guoming Chen, Pingping Chen, Po-An Chen, Shaomin Chen, Xurong Chen, Yixue Chen, Yu Chen, Zhiyuan Chen, Zikang Chen, Jie Cheng, Yaping Cheng, Alexander Chepurnov, Alexey Chetverikov, Davide Chiesa, Pietro Chimenti, Artem Chukanov, Gérard Claverie, Catia Clementi, Barbara Clerbaux, Marta Colomer Molla, Selma Conforti Di Lorenzo, Daniele Corti, Flavio Dal Corso, Olivia Dalager, Christophe De La Taille, Zhi Deng, Ziyan Deng, Wilfried Depnering, Marco Diaz, Xuefeng Ding, Yayun Ding, Bayu Dirgantara, Sergey Dmitrievsky, Tadeas Dohnal, Dmitry Dolzhikov, Georgy Donchenko, Jianmeng Dong, Evgeny Doroshkevich, Marcos Dracos, Frédéric Druillole, Ran Du, Shuxian Du, Stefano Dusini, Martin Dvorak, Timo Enqvist, Heike Enzmann, Andrea Fabbri, Donghua Fan, Lei Fan, Jian Fang, Wenxing Fang, Marco Fargetta, Dmitry Fedoseev, Zhengyong Fei, Li-Cheng Feng, Qichun Feng, Richard Ford, Amélie Fournier, Haonan Gan, Feng Gao, Alberto Garfagnini, Arsenii Gavrikov, Marco Giammarchi, Nunzio Giudice, Maxim Gonchar, Guanghua Gong, Hui Gong, Yuri Gornushkin, Alexandre Göttel, Marco Grassi, Maxim Gromov, Vasily Gromov, Minghao Gu, Xiaofei Gu, Yu Gu, Mengyun Guan, Yuduo Guan, Nunzio Guardone, Cong Guo, Jingyuan Guo, Wanlei Guo, Xinheng Guo, Yuhang Guo, Paul Hackspacher, Caren Hagner, Ran Han, Yang Han, Miao He, Wei He, Tobias Heinz, Patrick Hellmuth, Yuekun Heng, Rafael Herrera, YuenKeung Hor, Shaojing Hou, Yee Hsiung, Bei-Zhen Hu, Hang Hu, Jianrun Hu, Jun Hu, Shouyang Hu, Tao Hu, Yuxiang Hu, Zhuojun Hu, Guihong Huang, Hanxiong Huang, Kaixuan Huang, Wenhao Huang, Xin Huang, Xingtao Huang, Yongbo Huang, Jiaqi Hui, Lei Huo, Wenju Huo, Cédric Huss, Safeer Hussain, Ara Ioannisian, Roberto Isocrate, Beatrice Jelmini, Ignacio Jeria, Xiaolu Ji, Huihui Jia, Junji Jia, Siyu Jian, Di Jiang, Wei Jiang, Xiaoshan Jiang, Xiaoping Jing, Cécile Jollet, Leonidas Kalousis, Philipp Kampmann, Li Kang, Rebin Karaparambil, Narine Kazarian, Amina Khatun, Khanchai Khosonthongkee, Denis Korablev, Konstantin Kouzakov, Alexey Krasnoperov, Nikolay Kutovskiy, Pasi Kuusiniemi, Tobias Lachenmaier, Cecilia Landini, Sébastien Leblanc, Victor Lebrin, Frederic Lefevre, Ruiting Lei, Rupert Leitner, Jason Leung, Daozheng Li, Demin Li, Fei Li, Fule Li, Gaosong Li, Huiling Li, Mengzhao Li, Min Li, Nan Li, Qingjiang Li, Ruhui Li, Rui Li, Shanfeng Li, Tao Li, Teng Li, Weidong Li, Weiguo Li, Xiaomei Li, Xiaonan Li, Xinglong Li, Yi Li, Yichen Li, Zepeng Li, Zhaohan Li, Zhibing Li, Ziyuan Li, Zonghai Li, Hao Liang, Jiajun Liao, Ayut Limphirat, Guey-Lin Lin, Shengxin Lin, Tao Lin, Ivano Lippi, Fang Liu, Haidong Liu, Haotian Liu, Hongbang Liu, Hongjuan Liu, Hongtao Liu, Hui Liu, Jianglai Liu, Jinchang Liu, Min Liu, Qian Liu, Qin Liu, Runxuan Liu, Shubin Liu, Shulin Liu, Xiaowei Liu, Xiwen Liu, Yan Liu, Yunzhe Liu, Alexey Lokhov, Paolo Lombardi, Claudio Lombardo, Kai Loo, Chuan Lu, Jingbin Lu, Junguang Lu, Shuxiang Lu, Bayarto Lubsandorzhiev, Sultim Lubsandorzhiev, Livia Ludhova, Arslan Lukanov, Daibin Luo, Fengjiao Luo, Guang Luo, Shu Luo, Wuming Luo, Xiaojie Luo, Vladimir Lyashuk, Bangzheng Ma, Bing Ma, Qiumei Ma, Si Ma, Xiaoyan Ma, Xubo Ma, Jihane Maalmi, Jingyu Mai, Yury Malyshkin, Roberto Carlos Mandujano, Fabio Mantovani, Francesco Manzali, Xin Mao, Yajun Mao, Stefano M. Mari, Filippo Marini, Cristina Martellini, Gisele Martin-Chassard, Agnese Martini, Matthias Mayer, Davit Mayilyan, Ints Mednieks, Yue Meng, Anselmo Meregaglia, Emanuela Meroni, David Meyhöfer, Mauro Mezzetto, Jonathan Miller, Lino Miramonti, Paolo Montini, Michele Montuschi, Axel Müller, Massimiliano Nastasi, Dmitry V. Naumov, Elena Naumova, Diana Navas-Nicolas, Igor Nemchenok, Minh Thuan Nguyen Thi, Alexey Nikolaev, Feipeng Ning, Zhe Ning, Hiroshi Nunokawa, Lothar Oberauer, Juan Pedro Ochoa-Ricoux, Alexander Olshevskiy, Domizia Orestano, Fausto Ortica, Rainer Othegraven, Alessandro Paoloni, Sergio Parmeggiano, Yatian Pei, Nicomede Pelliccia, Anguo Peng, Haiping Peng, Yu Peng, Zhaoyuan Peng, Frédéric Perrot, Pierre-Alexandre Petitjean, Fabrizio Petrucci, Oliver Pilarczyk, Luis Felipe Piñeres Rico, Artyom Popov, Pascal Poussot, Ezio Previtali, Fazhi Qi, Ming Qi, Sen Qian, Xiaohui Qian, Zhen Qian, Hao Qiao, Zhonghua Qin, Shoukang Qiu, Gioacchino Ranucci, Neill Raper, Alessandra Re, Henning Rebber, Abdel Rebii, Mariia Redchuk, Bin Ren, Jie Ren, Barbara Ricci, Mariam Rifai, Mathieu Roche, Narongkiat Rodphai, Aldo Romani, Bedřich Roskovec, Xichao Ruan, Arseniy Rybnikov, Andrey Sadovsky, Paolo Saggese, Simone Sanfilippo, Anut Sangka, Utane Sawangwit, Julia Sawatzki, Michaela Schever, Cédric Schwab, Konstantin Schweizer, Alexandr Selyunin, Andrea Serafini, Giulio Settanta, Mariangela Settimo, Zhuang Shao, Vladislav Sharov, Arina Shaydurova, Jingyan Shi, Yanan Shi, Vitaly Shutov, Andrey Sidorenkov, Fedor Šimkovic, Chiara Sirignano, Jaruchit Siripak, Monica Sisti, Maciej Slupecki, Mikhail Smirnov, Oleg Smirnov, Thiago Sogo-Bezerra, Sergey Sokolov, Julanan Songwadhana, Boonrucksar Soonthornthum, Albert Sotnikov, Ondřej Šrámek, Warintorn Sreethawong, Achim Stahl, Luca Stanco, Konstantin Stankevich, Dušan Štefánik, Hans Steiger, Jochen Steinmann, Tobias Sterr, Matthias Raphael Stock, Virginia Strati, Alexander Studenikin, Jun Su, Shifeng Sun, Xilei Sun, Yongjie Sun, Yongzhao Sun, Zhengyang Sun, Narumon Suwonjandee, Michal Szelezniak, Jian Tang, Qiang Tang, Quan Tang, Xiao Tang, Alexander Tietzsch, Igor Tkachev, Tomas Tmej, Marco Danilo Claudio Torri, Konstantin Treskov, Andrea Triossi, Giancarlo Troni, Wladyslaw Trzaska, Cristina Tuve, Nikita Ushakov, Vadim Vedin, Giuseppe Verde, Maxim Vialkov, Benoit Viaud, Cornelius Moritz Vollbrecht, Cristina Volpe, Katharina von Sturm, Vit Vorobel, Dmitriy Voronin, Lucia Votano, Pablo Walker, Caishen Wang, Chung-Hsiang Wang, En Wang, Guoli Wang, Jian Wang, Jun Wang, Lu Wang, Meifen Wang, Meng Wang, Ruiguang Wang, Siguang Wang, Wei Wang, Wenshuai Wang, Xi Wang, Xiangyue Wang, Yangfu Wang, Yaoguang Wang, Yi Wang, Yifang Wang, Yuanqing Wang, Yuman Wang, Zhe Wang, Zheng Wang, Zhimin Wang, Zongyi Wang, Apimook Watcharangkool, Wei Wei, Wenlu Wei, Yadong Wei, Kaile Wen, Liangjian Wen, Christopher Wiebusch, Steven Chan-Fai Wong, Bjoern Wonsak, Diru Wu, Qun Wu, Zhi Wu, Michael Wurm, Jacques Wurtz, Christian Wysotzki, Yufei Xi, Dongmei Xia, Xiang Xiao, Xiaochuan Xie, Yuguang Xie, Zhangquan Xie, Zhao Xin, Zhizhong Xing, Benda Xu, Cheng Xu, Donglian Xu, Fanrong Xu, Hangkun Xu, Jilei Xu, Jing Xu, Meihang Xu, Yin Xu, Yu Xu, Baojun Yan, Taylor Yan, Wenqi Yan, Xiongbo Yan, Yupeng Yan, Changgen Yang, Chengfeng Yang, Huan Yang, Jie Yang, Lei Yang, Xiaoyu Yang, Yifan Yang, Haifeng Yao, Jiaxuan Ye, Mei Ye, Ziping Ye, Frédéric Yermia, Na Yin, Zhengyun You, Boxiang Yu, Chiye Yu, Chunxu Yu, Hongzhao Yu, Miao Yu, Xianghui Yu, Zezhong Yu, Cenxi Yuan, Chengzhuo Yuan, Ying Yuan, Zhenxiong Yuan, Noman Zafar, Vitalii Zavadskyi, Shan Zeng, Tingxuan Zeng, Yuda Zeng, Liang Zhan, Aiqiang Zhang, Bin Zhang, Binting Zhang, Feiyang Zhang, Guoqing Zhang, Honghao Zhang, Jialiang Zhang, Jiawen Zhang, Jie Zhang, Jin Zhang, Jingbo Zhang, Jinnan Zhang, Mohan Zhang, Peng Zhang, Qingmin Zhang, Shiqi Zhang, Shu Zhang, Tao Zhang, Xiaomei Zhang, Xin Zhang, Xuantong Zhang, Xueyao Zhang, Yinhong Zhang, Yiyu Zhang, Yongpeng Zhang, Yu Zhang, Yuanyuan Zhang, Yumei Zhang, Zhenyu Zhang, Zhijian Zhang, Fengyi Zhao, Rong Zhao, Runze Zhao, Shujun Zhao, Dongqin Zheng, Hua Zheng, Yangheng Zheng, Weirong Zhong, Jing Zhou, Li Zhou, Nan Zhou, Shun Zhou, Tong Zhou, Xiang Zhou, Jiang Zhu, Jingsen Zhu, Kangfu Zhu, Kejun Zhu, Zhihang Zhu, Bo Zhuang, Honglin Zhuang, Liang Zong, and Jiaheng Zou

Subjects
Solar neutrinos, Astrophysics, QB460-466
Abstract

The physics potential of detecting ^8 B solar neutrinos will be exploited at the Jiangmen Underground Neutrino Observatory (JUNO), in a model-independent manner by using three distinct channels of the charged current (CC), neutral current (NC), and elastic scattering (ES) interactions. Due to the largest-ever mass of ^13 C nuclei in the liquid scintillator detectors and the expected low background level, ^8 B solar neutrinos are observable in the CC and NC interactions on ^13 C for the first time. By virtue of optimized event selections and muon veto strategies, backgrounds from the accidental coincidence, muon-induced isotopes, and external backgrounds can be greatly suppressed. Excellent signal-to-background ratios can be achieved in the CC, NC, and ES channels to guarantee the observation of the ^8 B solar neutrinos. From the sensitivity studies performed in this work, we show that JUNO, with 10 yr of data, can reach the 1 σ precision levels of 5%, 8%, and 20% for the ^8 B neutrino flux, ${\sin }^{2}{\theta }_{12}$ , and ${\rm{\Delta }}{m}_{21}^{2}$ , respectively. Probing the details of both solar physics and neutrino physics would be unique and helpful. In addition, when combined with the Sudbury Neutrino Observatory measurement, the world's best precision of 3% is expected for the measurement of the ^8 B neutrino flux.

Published
2024
Full Text
View/download PDF

14. Acute Macular Neuroretinopathy after SARS-CoV-2 Infection: An Analysis of Clinical and Multimodal Imaging Characteristics

Author

Jiyang Tang, Siying Li, Zongyi Wang, Ye Tao, Linqi Zhang, Hong Yin, Heng Miao, Yaoyao Sun, and Jinfeng Qu

Subjects
acute macular neuroretinopathy, SARS-CoV-2, multimodal imaging, Medicine (General), R5-920
Abstract

Background: This study aimed to analyze clinical and multimodal imaging characteristics of acute macular neuroretinopathy (AMN) post-recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: Retrospective observational study. Medical records and multimodal imaging of 12 AMN eyes of eight patients (six female and two male) with recent SARS-CoV-2 infection were retrospectively analyzed. Results: Four patients (50%) presented with bilateral AMN. Fundus ophthalmoscopy revealed a reddish-brown lesion around the macula, and two eyes had cotton-wool spots at the posterior pole. Three eyes showed mild hypo-autofluorescence. All FFA images (7 eyes) showed no abnormal signs. On OCT scans, all eyes showed outer nuclear layer (ONL) thinning, 8 eyes (66.7%) showed ONL hyperreflectivity, 5 eyes (41.7%) showed outer plexiform layer (OPL) hyperreflectivity, 8 eyes (66.7%) showed interdigitation zone (IZ) disruption, 11 eyes (91.6%) showed ellipsoid zone (EZ) disruption, 2 eyes (16.7%) showed cotton-wool spots and inner plexiform layer (IPL) hyperreflectivity, 1 eye (8.3%) had intraretinal cyst and 1 eye (8.3%) had inner nuclear layer (INL) thinning. Persistent scotoma, ONL hyperreflectivity and IZ/EZ disruption as well as recovery of OPL hyperreflectivity were reported after follow-up in three cases. Conclusions: AMN post-SARS-CoV-2 mostly affected young females and could present unilaterally or bilaterally. Dark lesions on IR reflectance and outer retinal hyperreflectivity on OCT are useful in diagnosing AMN. OPL/ONL hyperreflectivity on OCT could disappear after follow-up, but ONL thinning and IZ/EZ could persist.

Published
2023
Full Text
View/download PDF

15. Correlation between Patient‐Derived Xenograft Modeling and Prognosis in Osteosarcoma

Author

Mengxiong Sun, Zongyi Wang, Wei Sun, Ming Chen, Xiaojun Ma, Jiakang Shen, Zeze Fu, Dongqing Zuo, Gangyang Wang, Hongsheng Wang, Chongren Wang, Fei Yin, Zhuoying Wang, Chuanying Zhang, Yingqi Hua, and Zhengdong Cai

Subjects
Chemotherapy, Osteosarcoma, Patient‐derived xenograft, Prognosis, Orthopedic surgery, RD701-811
Abstract

Objective To retrospectively analyze and compare the relationship between the success rate of patient‐derived xenograft (PDX) modeling of osteosarcoma and prognosis (3‐year overall survival rate and disease‐free survival rate) and incidence of lung metastasis. Methods The sample group consisted of 57 osteosarcoma patients with definite pathological diagnoses from Shanghai General Hospital from 2015–2017. PDX models in 57 patients were analyzed by retrospective analyses. Among the patients currently inoculated, 20 were tumorigenic in the PDX model, and 37 were nontumorigenic. According to the tumorigenicity of PDXs, the corresponding osteosarcoma patients were divided into two groups. The effects of clinically related indicators on the model were retrospectively compared. The patients were followed, and the 3‐year survival, 3‐year disease‐free survival (DFS), and lung metastasis rates were collected. The relationship between the modeling success and patient prognosis was investigated. Results In the chemotherapy‐treated group, the PDX modeling success rate was 17.4%, and in the nonchemotherapy group, the success rate was 47.1%. The success of PDX modeling was related to whether patients received chemotherapy. The success rate of PDX modeling is significantly reduced after receiving chemotherapy. The 3‐year overall survival rate of the PDX‐grafted group was 49.23%, and that of the PDX‐nongrafted group was 65.71%. There was a significant difference between the two groups, showing a strong negative correlation between the 3‐year survival rate and the success rate of the PDX model. The 3‐year disease‐free survival rate of the PDX‐grafted group was 29.54%. The 3‐year DFS of the PDX‐nongrafted group was 50.34%. There was a significant difference between the two groups. Lower grafted rates indicate a higher DFS rate. The incidence of lung metastasis in the PDX‐grafted group was 32.4%, and that in the nongrafted group was 13.1%. There was a significant difference between the two groups. The successful establishment of the PDX model indicates that patients are more likely to have lung metastases. Conclusions The success of PDX modeling often indicates poor prognosis (low 3‐year overall survival rate and disease‐free survival rate) and a greater possibility of lung metastasis. Therefore, PDX modeling in osteosarcoma patients can accurately predict the prognosis of patients and the risk of lung metastasis in advance to help us develop better therapeutic strategies.

Published
2022
Full Text
View/download PDF

16. Case series: pachychoroid pigment epitheliopathy transformed to polypoidal choroidal vasculopathy after long-term follow-up

Author

Jiyang Tang, Xinyao Han, Ran Tang, Mengyang Li, Zongyi Wang, Mingwei Zhao, and Jinfeng Qu

Subjects
Pachychoroid, Pachychoroid pigment epitheliopathy, Polypoidal choroidal vasculopathy, Pachychoroid spectrum diseases, Ophthalmology, RE1-994
Abstract

Abstract Background Pachychoroid pigment epitheliopathy (PPE), a retinal disorder that falls into the pachychoroid spectrum, is characterized by retinal pigment epithelium changes in pachychoroid eyes without existing or previous subretinal fluid or soft drusen. Previous reports have indicated that PPE may share some pathophysiologic component with other pachychoroid spectrum diseases and could transform into central serous chorioretinopathy (CSC) during follow-up. CSC transformation to PNV and PCV has also been reported, but PPE transformation to PCV has not been reported. Case presentation Seven eyes of seven patients (four male three female, aged 62.7 ± 8.4 years) who presented with PPE at baseline transformed to PCV during follow-up. All study eyes had baseline contralateral eye diagnoses of PCV. All PPE eyes reported no symptoms at baseline and were followed up regularly for the treatment of their contralateral eyes. All PPE presented as pigment epithelium detachment (PED) at baseline. The mean central macular thickness (CMT) was 217.6 ± 14.6 µm, the mean subfoveal choroidal thickness (SFCT) was 354.9 ± 94.9 µm, and the mean sub-PPE choroidal thickness was 332.3 ± 84.6 µm. The mean PPE width and height were 1326.4 ± 791.4 µm and 58.7 ± 23.6 µm, respectively, at baseline. Disruption of the ellipsoid zone (EZ) was noted in 3 eyes, while choroidal vascular hyperpermeability (CVH) was noted in 5 eyes at baseline. The follow-up period was 75.0 ± 41.1 months, and the mean transformation time was 49.6 ± 24.8 months. All study eyes received no intervention before transformation. Conclusions PPE could transform to PCV after a long follow-up period. Regular follow-ups for a long time should be recommended for patients with PPE.

Published
2022
Full Text
View/download PDF

17. Damping signatures at JUNO, a medium-baseline reactor neutrino oscillation experiment

Author

The JUNO collaboration, Jun Wang, Jiajun Liao, Wei Wang, Angel Abusleme, Thomas Adam, Shakeel Ahmad, Rizwan Ahmed, Sebastiano Aiello, Muhammad Akram, Fengpeng An, Qi An, Giuseppe Andronico, Nikolay Anfimov, Vito Antonelli, Tatiana Antoshkina, Burin Asavapibhop, João Pedro Athayde Marcondes de André, Didier Auguste, Andrej Babic, Nikita Balashov, Wander Baldini, Andrea Barresi, Davide Basilico, Eric Baussan, Marco Bellato, Antonio Bergnoli, Thilo Birkenfeld, Sylvie Blin, David Blum, Simon Blyth, Anastasia Bolshakova, Mathieu Bongrand, Clément Bordereau, Dominique Breton, Augusto Brigatti, Riccardo Brugnera, Riccardo Bruno, Antonio Budano, Mario Buscemi, Jose Busto, Ilya Butorov, Anatael Cabrera, Hao Cai, Xiao Cai, Yanke Cai, Zhiyan Cai, Riccardo Callegari, Antonio Cammi, Agustin Campeny, Chuanya Cao, Guofu Cao, Jun Cao, Rossella Caruso, Cédric Cerna, Jinfan Chang, Yun Chang, Pingping Chen, Po-An Chen, Shaomin Chen, Xurong Chen, Yi-Wen Chen, Yixue Chen, Yu Chen, Zhang Chen, Jie Cheng, Yaping Cheng, Alexey Chetverikov, Davide Chiesa, Pietro Chimenti, Artem Chukanov, Gérard Claverie, Catia Clementi, Barbara Clerbaux, Selma Conforti Di Lorenzo, Daniele Corti, Flavio Dal Corso, Olivia Dalager, Christophe De La Taille, Jiawei Deng, Zhi Deng, Ziyan Deng, Wilfried Depnering, Marco Diaz, Xuefeng Ding, Yayun Ding, Bayu Dirgantara, Sergey Dmitrievsky, Tadeas Dohnal, Dmitry Dolzhikov, Georgy Donchenko, Jianmeng Dong, Evgeny Doroshkevich, Marcos Dracos, Frédéric Druillole, Ran Du, Shuxian Du, Stefano Dusini, Martin Dvorak, Timo Enqvist, Heike Enzmann, Andrea Fabbri, Lukas Fajt, Donghua Fan, Lei Fan, Jian Fang, Wenxing Fang, Marco Fargetta, Dmitry Fedoseev, Vladko Fekete, Li-Cheng Feng, Qichun Feng, Richard Ford, Amélie Fournier, Haonan Gan, Feng Gao, Alberto Garfagnini, Arsenii Gavrikov, Marco Giammarchi, Agnese Giaz, Nunzio Giudice, Maxim Gonchar, Guanghua Gong, Hui Gong, Yuri Gornushkin, Alexandre Göttel, Marco Grassi, Christian Grewing, Vasily Gromov, Minghao Gu, Xiaofei Gu, Yu Gu, Mengyun Guan, Nunzio Guardone, Maria Gul, Cong Guo, Jingyuan Guo, Wanlei Guo, Xinheng Guo, Yuhang Guo, Paul Hackspacher, Caren Hagner, Ran Han, Yang Han, Muhammad Sohaib Hassan, Miao He, Wei He, Tobias Heinz, Patrick Hellmuth, Yuekun Heng, Rafael Herrera, YuenKeung Hor, Shaojing Hou, Yee Hsiung, Bei-Zhen Hu, Hang Hu, Jianrun Hu, Jun Hu, Shouyang Hu, Tao Hu, Zhuojun Hu, Chunhao Huang, Guihong Huang, Hanxiong Huang, Wenhao Huang, Xin Huang, Xingtao Huang, Yongbo Huang, Jiaqi Hui, Lei Huo, Wenju Huo, Cédric Huss, Safeer Hussain, Ara Ioannisian, Roberto Isocrate, Beatrice Jelmini, Kuo-Lun Jen, Ignacio Jeria, Xiaolu Ji, Xingzhao Ji, Huihui Jia, Junji Jia, Siyu Jian, Di Jiang, Wei Jiang, Xiaoshan Jiang, Ruyi Jin, Xiaoping Jing, Cécile Jollet, Jari Joutsenvaara, Sirichok Jungthawan, Leonidas Kalousis, Philipp Kampmann, Li Kang, Rebin Karaparambil, Narine Kazarian, Khanchai Khosonthongkee, Denis Korablev, Konstantin Kouzakov, Alexey Krasnoperov, Andre Kruth, Nikolay Kutovskiy, Pasi Kuusiniemi, Tobias Lachenmaier, Cecilia Landini, Sébastien Leblanc, Victor Lebrin, Frederic Lefevre, Ruiting Lei, Rupert Leitner, Jason Leung, Demin Li, Fei Li, Fule Li, Haitao Li, Huiling Li, Jiaqi Li, Mengzhao Li, Min Li, Nan Li, Qingjiang Li, Ruhui Li, Shanfeng Li, Tao Li, Weidong Li, Weiguo Li, Xiaomei Li, Xiaonan Li, Xinglong Li, Yi Li, Yufeng Li, Zhaohan Li, Zhibing Li, Ziyuan Li, Hao Liang, Daniel Liebau, Ayut Limphirat, Sukit Limpijumnong, Guey-Lin Lin, Shengxin Lin, Tao Lin, Jiajie Ling, Ivano Lippi, Fang Liu, Haidong Liu, Hongbang Liu, Hongjuan Liu, Hongtao Liu, Hui Liu, Jianglai Liu, Jinchang Liu, Min Liu, Qian Liu, Qin Liu, Runxuan Liu, Shuangyu Liu, Shubin Liu, Shulin Liu, Xiaowei Liu, Xiwen Liu, Yan Liu, Yunzhe Liu, Alexey Lokhov, Paolo Lombardi, Claudio Lombardo, Kai Loo, Chuan Lu, Haoqi Lu, Jingbin Lu, Junguang Lu, Shuxiang Lu, Xiaoxu Lu, Bayarto Lubsandorzhiev, Sultim Lubsandorzhiev, Livia Ludhova, Arslan Lukanov, Fengjiao Luo, Guang Luo, Pengwei Luo, Shu Luo, Wuming Luo, Vladimir Lyashuk, Bangzheng Ma, Qiumei Ma, Si Ma, Xiaoyan Ma, Xubo Ma, Jihane Maalmi, Yury Malyshkin, Roberto Carlos Mandujano, Fabio Mantovani, Francesco Manzali, Xin Mao, Yajun Mao, Stefano M. Mari, Filippo Marini, Sadia Marium, Cristina Martellini, Gisele Martin-Chassard, Agnese Martini, Matthias Mayer, Davit Mayilyan, Ints Mednieks, Yue Meng, Anselmo Meregaglia, Emanuela Meroni, David Meyhöfer, Mauro Mezzetto, Jonathan Miller, Lino Miramonti, Paolo Montini, Michele Montuschi, Axel Müller, Massimiliano Nastasi, Dmitry V. Naumov, Elena Naumova, Diana Navas-Nicolas, Igor Nemchenok, Minh Thuan Nguyen Thi, Feipeng Ning, Zhe Ning, Hiroshi Nunokawa, Lothar Oberauer, Juan Pedro Ochoa-Ricoux, Alexander Olshevskiy, Domizia Orestano, Fausto Ortica, Rainer Othegraven, Hsiao-Ru Pan, Alessandro Paoloni, Sergio Parmeggiano, Yatian Pei, Nicomede Pelliccia, Anguo Peng, Haiping Peng, Frédéric Perrot, Pierre-Alexandre Petitjean, Fabrizio Petrucci, Oliver Pilarczyk, Luis Felipe Piñeres Rico, Artyom Popov, Pascal Poussot, Wathan Pratumwan, Ezio Previtali, Fazhi Qi, Ming Qi, Sen Qian, Xiaohui Qian, Zhen Qian, Hao Qiao, Zhonghua Qin, Shoukang Qiu, Muhammad Usman Rajput, Gioacchino Ranucci, Neill Raper, Alessandra Re, Henning Rebber, Abdel Rebii, Bin Ren, Jie Ren, Barbara Ricci, Markus Robens, Mathieu Roche, Narongkiat Rodphai, Aldo Romani, Bedřich Roskovec, Christian Roth, Xiangdong Ruan, Xichao Ruan, Saroj Rujirawat, Arseniy Rybnikov, Andrey Sadovsky, Paolo Saggese, Simone Sanfilippo, Anut Sangka, Nuanwan Sanguansak, Utane Sawangwit, Julia Sawatzki, Fatma Sawy, Michaela Schever, Cédric Schwab, Konstantin Schweizer, Alexandr Selyunin, Andrea Serafini, Giulio Settanta, Mariangela Settimo, Zhuang Shao, Vladislav Sharov, Arina Shaydurova, Jingyan Shi, Yanan Shi, Vitaly Shutov, Andrey Sidorenkov, Fedor Šimkovic, Chiara Sirignano, Jaruchit Siripak, Monica Sisti, Maciej Slupecki, Mikhail Smirnov, Oleg Smirnov, Thiago Sogo-Bezerra, Sergey Sokolov, Julanan Songwadhana, Boonrucksar Soonthornthum, Albert Sotnikov, Ondřej Šrámek, Warintorn Sreethawong, Achim Stahl, Luca Stanco, Konstantin Stankevich, Dušan Štefánik, Hans Steiger, Jochen Steinmann, Tobias Sterr, Matthias Raphael Stock, Virginia Strati, Alexander Studenikin, Shifeng Sun, Xilei Sun, Yongjie Sun, Yongzhao Sun, Narumon Suwonjandee, Michal Szelezniak, Jian Tang, Qiang Tang, Quan Tang, Xiao Tang, Alexander Tietzsch, Igor Tkachev, Tomas Tmej, Marco Danilo Claudio Torri, Konstantin Treskov, Andrea Triossi, Giancarlo Troni, Wladyslaw Trzaska, Cristina Tuve, Nikita Ushakov, Johannes van den Boom, Stefan van Waasen, Guillaume Vanroyen, Vadim Vedin, Giuseppe Verde, Maxim Vialkov, Benoit Viaud, Cornelius Moritz Vollbrecht, Cristina Volpe, Vit Vorobel, Dmitriy Voronin, Lucia Votano, Pablo Walker, Caishen Wang, Chung-Hsiang Wang, En Wang, Guoli Wang, Jian Wang, Kunyu Wang, Lu Wang, Meifen Wang, Meng Wang, Ruiguang Wang, Siguang Wang, Wenshuai Wang, Xi Wang, Xiangyue Wang, Yangfu Wang, Yaoguang Wang, Yi Wang, Yifang Wang, Yuanqing Wang, Yuman Wang, Zhe Wang, Zheng Wang, Zhimin Wang, Zongyi Wang, Muhammad Waqas, Apimook Watcharangkool, Lianghong Wei, Wei Wei, Wenlu Wei, Yadong Wei, Kaile Wen, Liangjian Wen, Christopher Wiebusch, Steven Chan-Fai Wong, Bjoern Wonsak, Diru Wu, Qun Wu, Zhi Wu, Michael Wurm, Jacques Wurtz, Christian Wysotzki, Yufei Xi, Dongmei Xia, Xiaochuan Xie, Yuguang Xie, Zhangquan Xie, Zhizhong Xing, Benda Xu, Cheng Xu, Donglian Xu, Fanrong Xu, Hangkun Xu, Jilei Xu, Jing Xu, Meihang Xu, Yin Xu, Yu Xu, Baojun Yan, Taylor Yan, Wenqi Yan, Xiongbo Yan, Yupeng Yan, Anbo Yang, Changgen Yang, Chengfeng Yang, Huan Yang, Jie Yang, Lei Yang, Xiaoyu Yang, Yifan Yang, Haifeng Yao, Zafar Yasin, Jiaxuan Ye, Mei Ye, Ziping Ye, Ugur Yegin, Frédéric Yermia, Peihuai Yi, Na Yin, Xiangwei Yin, Zhengyun You, Boxiang Yu, Chiye Yu, Chunxu Yu, Hongzhao Yu, Miao Yu, Xianghui Yu, Zeyuan Yu, Zezhong Yu, Chengzhuo Yuan, Ying Yuan, Zhenxiong Yuan, Ziyi Yuan, Baobiao Yue, Noman Zafar, Andre Zambanini, Vitalii Zavadskyi, Shan Zeng, Tingxuan Zeng, Yuda Zeng, Liang Zhan, Aiqiang Zhang, Feiyang Zhang, Guoqing Zhang, Haiqiong Zhang, Honghao Zhang, Jiawen Zhang, Jie Zhang, Jin Zhang, Jingbo Zhang, Jinnan Zhang, Peng Zhang, Qingmin Zhang, Shiqi Zhang, Shu Zhang, Tao Zhang, Xiaomei Zhang, Xuantong Zhang, Xueyao Zhang, Yan Zhang, Yinhong Zhang, Yiyu Zhang, Yongpeng Zhang, Yuanyuan Zhang, Yumei Zhang, Zhenyu Zhang, Zhijian Zhang, Fengyi Zhao, Jie Zhao, Rong Zhao, Shujun Zhao, Tianchi Zhao, Dongqin Zheng, Hua Zheng, Minshan Zheng, Yangheng Zheng, Weirong Zhong, Jing Zhou, Li Zhou, Nan Zhou, Shun Zhou, Tong Zhou, Xiang Zhou, Jiang Zhu, Kangfu Zhu, Kejun Zhu, Zhihang Zhu, Bo Zhuang, Honglin Zhuang, Liang Zong, and Jiaheng Zou

Subjects
Neutrino Detectors and Telescopes (experiments), Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Abstract We study damping signatures at the Jiangmen Underground Neutrino Observatory (JUNO), a medium-baseline reactor neutrino oscillation experiment. These damping signatures are motivated by various new physics models, including quantum decoherence, ν 3 decay, neutrino absorption, and wave packet decoherence. The phenomenological effects of these models can be characterized by exponential damping factors at the probability level. We assess how well JUNO can constrain these damping parameters and how to disentangle these different damping signatures at JUNO. Compared to current experimental limits, JUNO can significantly improve the limits on τ 3/m 3 in the ν 3 decay model, the width of the neutrino wave packet σ x , and the intrinsic relative dispersion of neutrino momentum σ rel.

Published
2022
Full Text
View/download PDF

18. The design and sensitivity of JUNO’s scintillator radiopurity pre-detector OSIRIS

Author

Angel Abusleme, Thomas Adam, Shakeel Ahmad, Rizwan Ahmed, Sebastiano Aiello, Muhammad Akram, Fengpeng An, Guangpeng An, Qi An, Giuseppe Andronico, Nikolay Anfimov, Vito Antonelli, Tatiana Antoshkina, Burin Asavapibhop, João Pedro Athayde Marcondes de André, Didier Auguste, Andrej Babic, Wander Baldini, Andrea Barresi, Davide Basilico, Eric Baussan, Marco Bellato, Antonio Bergnoli, Thilo Birkenfeld, Sylvie Blin, David Blum, Simon Blyth, Anastasia Bolshakova, Mathieu Bongrand, Clément Bordereau, Dominique Breton, Augusto Brigatti, Riccardo Brugnera, Riccardo Bruno, Antonio Budano, Mario Buscemi, Jose Busto, Ilya Butorov, Anatael Cabrera, Hao Cai, Xiao Cai, Yanke Cai, Zhiyan Cai, Antonio Cammi, Agustin Campeny, Chuanya Cao, Guofu Cao, Jun Cao, Rossella Caruso, Cédric Cerna, Jinfan Chang, Yun Chang, Pingping Chen, Po-An Chen, Shaomin Chen, Xurong Chen, Yi-Wen Chen, Yixue Chen, Yu Chen, Zhang Chen, Jie Cheng, Yaping Cheng, Alexey Chetverikov, Davide Chiesa, Pietro Chimenti, Artem Chukanov, Gérard Claverie, Catia Clementi, Barbara Clerbaux, Selma Conforti Di Lorenzo, Daniele Corti, Salvatore Costa, Flavio Dal Corso, Olivia Dalager, Christophe De La Taille, Jiawei Deng, Zhi Deng, Ziyan Deng, Wilfried Depnering, Marco Diaz, Xuefeng Ding, Yayun Ding, Bayu Dirgantara, Sergey Dmitrievsky, Tadeas Dohnal, Dmitry Dolzhikov, Georgy Donchenko, Jianmeng Dong, Evgeny Doroshkevich, Marcos Dracos, Frédéric Druillole, Shuxian Du, Stefano Dusini, Martin Dvorak, Timo Enqvist, Heike Enzmann, Andrea Fabbri, Lukas Fajt, Donghua Fan, Lei Fan, Can Fang, Jian Fang, Wenxing Fang, Marco Fargetta, Dmitry Fedoseev, Vladko Fekete, Li-Cheng Feng, Qichun Feng, Richard Ford, Andrey Formozov, Amélie Fournier, Haonan Gan, Feng Gao, Alberto Garfagnini, Christoph Genster, Marco Giammarchi, Agnese Giaz, Nunzio Giudice, Maxim Gonchar, Guanghua Gong, Hui Gong, Yuri Gornushkin, Alexandre Göttel, Marco Grassi, Christian Grewing, Vasily Gromov, Minghao Gu, Xiaofei Gu, Yu Gu, Mengyun Guan, Nunzio Guardone, Maria Gul, Cong Guo, Jingyuan Guo, Wanlei Guo, Xinheng Guo, Yuhang Guo, Paul Hackspacher, Caren Hagner, Ran Han, Yang Han, Muhammad Sohaib Hassan, Miao He, Wei He, Tobias Heinz, Patrick Hellmuth, Yuekun Heng, Rafael Herrera, Daojin Hong, YuenKeung Hor, Shaojing Hou, Yee Hsiung, Bei-Zhen Hu, Hang Hu, Jianrun Hu, Jun Hu, Shouyang Hu, Tao Hu, Zhuojun Hu, Chunhao Huang, Guihong Huang, Hanxiong Huang, Wenhao Huang, Xin Huang, Xingtao Huang, Yongbo Huang, Jiaqi Hui, Lei Huo, Wenju Huo, Cédric Huss, Safeer Hussain, Ara Ioannisian, Roberto Isocrate, Beatrice Jelmini, Kuo-Lun Jen, Ignacio Jeria, Xiaolu Ji, Xingzhao Ji, Huihui Jia, Junji Jia, Siyu Jian, Di Jiang, Xiaoshan Jiang, Ruyi Jin, Xiaoping Jing, Cécile Jollet, Jari Joutsenvaara, Sirichok Jungthawan, Leonidas Kalousis, Philipp Kampmann, Li Kang, Michael Karagounis, Narine Kazarian, Waseem Khan, Khanchai Khosonthongkee, Denis Korablev, Konstantin Kouzakov, Alexey Krasnoperov, Andre Kruth, Nikolay Kutovskiy, Pasi Kuusiniemi, Tobias Lachenmaier, Cecilia Landini, Sébastien Leblanc, Victor Lebrin, Frederic Lefevre, Ruiting Lei, Rupert Leitner, Jason Leung, Demin Li, Fei Li, Fule Li, Haitao Li, Huiling Li, Jiaqi Li, Mengzhao Li, Min Li, Nan Li, Qingjiang Li, Ruhui Li, Shanfeng Li, Tao Li, Weidong Li, Weiguo Li, Xiaomei Li, Xiaonan Li, Xinglong Li, Yi Li, Yufeng Li, Zhaohan Li, Zhibing Li, Ziyuan Li, Hao Liang, Jingjing Liang, Jiajun Liao, Daniel Liebau, Ayut Limphirat, Sukit Limpijumnong, Guey-Lin Lin, Shengxin Lin, Tao Lin, Jiajie Ling, Ivano Lippi, Fang Liu, Haidong Liu, Hongbang Liu, Hongjuan Liu, Hongtao Liu, Hui Liu, Jianglai Liu, Jinchang Liu, Min Liu, Qian Liu, Qin Liu, Runxuan Liu, Shuangyu Liu, Shubin Liu, Shulin Liu, Xiaowei Liu, Xiwen Liu, Yan Liu, Yunzhe Liu, Alexey Lokhov, Paolo Lombardi, Claudio Lombardo, Kai Loo, Chuan Lu, Haoqi Lu, Jingbin Lu, Junguang Lu, Shuxiang Lu, Xiaoxu Lu, Bayarto Lubsandorzhiev, Sultim Lubsandorzhiev, Livia Ludhova, Fengjiao Luo, Guang Luo, Pengwei Luo, Shu Luo, Wuming Luo, Vladimir Lyashuk, Bangzheng Ma, Qiumei Ma, Si Ma, Xiaoyan Ma, Xubo Ma, Jihane Maalmi, Yury Malyshkin, Fabio Mantovani, Francesco Manzali, Xin Mao, Yajun Mao, Stefano M. Mari, Filippo Marini, Sadia Marium, Cristina Martellini, Gisele Martin-Chassard, Agnese Martini, Davit Mayilyan, Ints Mednieks, Yue Meng, Anselmo Meregaglia, Emanuela Meroni, David Meyhöfer, Mauro Mezzetto, Jonathan Miller, Lino Miramonti, Paolo Montini, Michele Montuschi, Axel Müller, Pavithra Muralidharan, Massimiliano Nastasi, Dmitry V. Naumov, Elena Naumova, Diana Navas-Nicolas, Igor Nemchenok, MinhThuan NguyenThi, Feipeng Ning, Zhe Ning, Hiroshi Nunokawa, Lothar Oberauer, Juan Pedro Ochoa-Ricoux, Alexander Olshevskiy, Domizia Orestano, Fausto Ortica, Rainer Othegraven, Hsiao-Ru Pan, Alessandro Paoloni, Nina Parkalian, Sergio Parmeggiano, Yatian Pei, Nicomede Pelliccia, Anguo Peng, Haiping Peng, Frédéric Perrot, Pierre-Alexandre Petitjean, Fabrizio Petrucci, Oliver Pilarczyk, Luis Felipe Piñeres Rico, Artyom Popov, Pascal Poussot, Wathan Pratumwan, Ezio Previtali, Fazhi Qi, Ming Qi, Sen Qian, Xiaohui Qian, Zhen Qian, Hao Qiao, Zhonghua Qin, Shoukang Qiu, Muhammad Usman Rajput, Gioacchino Ranucci, Neill Raper, Alessandra Re, Henning Rebber, Abdel Rebii, Bin Ren, Jie Ren, Barbara Ricci, Markus Robens, Mathieu Roche, Narongkiat Rodphai, Aldo Romani, Bedřich Roskovec, Christian Roth, Xiangdong Ruan, Xichao Ruan, Saroj Rujirawat, Arseniy Rybnikov, Andrey Sadovsky, Paolo Saggese, Simone Sanfilippo, Anut Sangka, Nuanwan Sanguansak, Utane Sawangwit, Julia Sawatzki, Fatma Sawy, Michaela Schever, Cédric Schwab, Konstantin Schweizer, Alexandr Selyunin, Andrea Serafini, Giulio Settanta, Mariangela Settimo, Zhuang Shao, Vladislav Sharov, Arina Shaydurova, Jingyan Shi, Yanan Shi, Vitaly Shutov, Andrey Sidorenkov, Fedor Šimkovic, Chiara Sirignano, Jaruchit Siripak, Monica Sisti, Maciej Slupecki, Mikhail Smirnov, Oleg Smirnov, Thiago Sogo-Bezerra, Sergey Sokolov, Julanan Songwadhana, Boonrucksar Soonthornthum, Albert Sotnikov, Ondřej Šrámek, Warintorn Sreethawong, Achim Stahl, Luca Stanco, Konstantin Stankevich, Dušan Štefánik, Hans Steiger, Jochen Steinmann, Tobias Sterr, Matthias Raphael Stock, Virginia Strati, Alexander Studenikin, Gongxing Sun, Shifeng Sun, Xilei Sun, Yongjie Sun, Yongzhao Sun, Narumon Suwonjandee, Michal Szelezniak, Jian Tang, Qiang Tang, Quan Tang, Xiao Tang, Alexander Tietzsch, Igor Tkachev, Tomas Tmej, Konstantin Treskov, Andrea Triossi, Giancarlo Troni, Wladyslaw Trzaska, Cristina Tuve, Nikita Ushakov, Johannes van den Boom, Stefan van Waasen, Guillaume Vanroyen, Nikolaos Vassilopoulos, Vadim Vedin, Giuseppe Verde, Maxim Vialkov, Benoit Viaud, Cornelius Vollbrecht, Cristina Volpe, Vit Vorobel, Dmitriy Voronin, Lucia Votano, Pablo Walker, Caishen Wang, Chung-Hsiang Wang, En Wang, Guoli Wang, Jian Wang, Jun Wang, Kunyu Wang, Lu Wang, Meifen Wang, Meng Wang, Ruiguang Wang, Siguang Wang, Wei Wang, Wenshuai Wang, Xi Wang, Xiangyue Wang, Yangfu Wang, Yaoguang Wang, Yi Wang, Yifang Wang, Yuanqing Wang, Yuman Wang, Zhe Wang, Zheng Wang, Zhimin Wang, Zongyi Wang, Muhammad Waqas, Apimook Watcharangkool, Lianghong Wei, Wei Wei, Wenlu Wei, Yadong Wei, Liangjian Wen, Christopher Wiebusch, Steven Chan-Fai Wong, Bjoern Wonsak, Diru Wu, Fangliang Wu, Qun Wu, Zhi Wu, Michael Wurm, Jacques Wurtz, Christian Wysotzki, Yufei Xi, Dongmei Xia, Yuguang Xie, Zhangquan Xie, Zhizhong Xing, Benda Xu, Cheng Xu, Donglian Xu, Fanrong Xu, Hangkun Xu, Jilei Xu, Jing Xu, Meihang Xu, Yin Xu, Yu Xu, Baojun Yan, Taylor Yan, Wenqi Yan, Xiongbo Yan, Yupeng Yan, Anbo Yang, Changgen Yang, Huan Yang, Jie Yang, Lei Yang, Xiaoyu Yang, Yifan Yang, Haifeng Yao, Zafar Yasin, Jiaxuan Ye, Mei Ye, Ziping Ye, Ugur Yegin, Frédéric Yermia, Peihuai Yi, Na Yin, Xiangwei Yin, Zhengyun You, Boxiang Yu, Chiye Yu, Chunxu Yu, Hongzhao Yu, Miao Yu, Xianghui Yu, Zeyuan Yu, Zezhong Yu, Chengzhuo Yuan, Ying Yuan, Zhenxiong Yuan, Ziyi Yuan, Baobiao Yue, Noman Zafar, Andre Zambanini, Vitalii Zavadskyi, Shan Zeng, Tingxuan Zeng, Yuda Zeng, Liang Zhan, Aiqiang Zhang, Feiyang Zhang, Guoqing Zhang, Haiqiong Zhang, Honghao Zhang, Jiawen Zhang, Jie Zhang, Jingbo Zhang, Jinnan Zhang, Peng Zhang, Qingmin Zhang, Shiqi Zhang, Shu Zhang, Tao Zhang, Xiaomei Zhang, Xuantong Zhang, Xueyao Zhang, Yan Zhang, Yinhong Zhang, Yiyu Zhang, Yongpeng Zhang, Yuanyuan Zhang, Yumei Zhang, Zhenyu Zhang, Zhijian Zhang, Fengyi Zhao, Jie Zhao, Rong Zhao, Shujun Zhao, Tianchi Zhao, Dongqin Zheng, Hua Zheng, Minshan Zheng, Yangheng Zheng, Weirong Zhong, Jing Zhou, Li Zhou, Nan Zhou, Shun Zhou, Tong Zhou, Xiang Zhou, Jiang Zhu, Kangpu Zhu, Kejun Zhu, Zhihang Zhu, Bo Zhuang, Honglin Zhuang, Liang Zong, Jiaheng Zou, and JUNO Collaboration

Subjects
Astrophysics, QB460-466, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Abstract The OSIRIS detector is a subsystem of the liquid scintillator filling chain of the JUNO reactor neutrino experiment. Its purpose is to validate the radiopurity of the scintillator to assure that all components of the JUNO scintillator system work to specifications and only neutrino-grade scintillator is filled into the JUNO Central Detector. The aspired sensitivity level of $$10^{-16}\hbox { g/g}$$ 10 - 16 g/g of $$^{238}\hbox {U}$$ 238 U and $$^{232}\hbox {Th}$$ 232 Th requires a large ( $$\sim 20\,\hbox {m}^3$$ ∼ 20 m 3 ) detection volume and ultralow background levels. The present paper reports on the design and major components of the OSIRIS detector, the detector simulation as well as the measuring strategies foreseen and the sensitivity levels to U/Th that can be reached in this setup.

Published
2021
Full Text
View/download PDF

19. Radioactivity control strategy for the JUNO detector

Author

The JUNO collaboration, Angel Abusleme, Thomas Adam, Shakeel Ahmad, Rizwan Ahmed, Sebastiano Aiello, Muhammad Akram, Fengpeng An, Qi An, Giuseppe Andronico, Nikolay Anfimov, Vito Antonelli, Tatiana Antoshkina, Burin Asavapibhop, João Pedro Athayde Marcondes de André, Didier Auguste, Andrej Babic, Wander Baldini, Andrea Barresi, Davide Basilico, Eric Baussan, Marco Bellato, Antonio Bergnoli, Thilo Birkenfeld, Sylvie Blin, David Blum, Simon Blyth, Anastasia Bolshakova, Mathieu Bongrand, Clément Bordereau, Dominique Breton, Augusto Brigatti, Riccardo Brugnera, Riccardo Bruno, Antonio Budano, Mario Buscemi, Jose Busto, Ilya Butorov, Anatael Cabrera, Hao Cai, Xiao Cai, Yanke Cai, Zhiyan Cai, Antonio Cammi, Agustin Campeny, Chuanya Cao, Guofu Cao, Jun Cao, Rossella Caruso, Cédric Cerna, Jinfan Chang, Yun Chang, Pingping Chen, Po-An Chen, Shaomin Chen, Xurong Chen, Yi-Wen Chen, Yixue Chen, Yu Chen, Zhang Chen, Jie Cheng, Yaping Cheng, Alexey Chetverikov, Davide Chiesa, Pietro Chimenti, Artem Chukanov, Gérard Claverie, Catia Clementi, Barbara Clerbaux, Selma Conforti Di Lorenzo, Daniele Corti, Oliviero Cremonesi, Flavio Dal Corso, Olivia Dalager, Christophe De La Taille, Jiawei Deng, Zhi Deng, Ziyan Deng, Wilfried Depnering, Marco Diaz, Xuefeng Ding, Yayun Ding, Bayu Dirgantara, Sergey Dmitrievsky, Tadeas Dohnal, Dmitry Dolzhikov, Georgy Donchenko, Jianmeng Dong, Evgeny Doroshkevich, Marcos Dracos, Frédéric Druillole, Shuxian Du, Stefano Dusini, Martin Dvorak, Timo Enqvist, Heike Enzmann, Andrea Fabbri, Lukas Fajt, Donghua Fan, Lei Fan, Jian Fang, Wenxing Fang, Marco Fargetta, Dmitry Fedoseev, Vladko Fekete, Li-Cheng Feng, Qichun Feng, Richard Ford, Andrey Formozov, Amélie Fournier, Haonan Gan, Feng Gao, Alberto Garfagnini, Marco Giammarchi, Agnese Giaz, Nunzio Giudice, Maxim Gonchar, Guanghua Gong, Hui Gong, Yuri Gornushkin, Alexandre Göttel, Marco Grassi, Christian Grewing, Vasily Gromov, Minghao Gu, Xiaofei Gu, Yu Gu, Mengyun Guan, Nunzio Guardone, Maria Gul, Cong Guo, Jingyuan Guo, Wanlei Guo, Xinheng Guo, Yuhang Guo, Paul Hackspacher, Caren Hagner, Ran Han, Yang Han, Muhammad Sohaib Hassan, Miao He, Wei He, Tobias Heinz, Patrick Hellmuth, Yuekun Heng, Rafael Herrera, YuenKeung Hor, Shaojing Hou, Yee Hsiung, Bei-Zhen Hu, Hang Hu, Jianrun Hu, Jun Hu, Shouyang Hu, Tao Hu, Zhuojun Hu, Chunhao Huang, Guihong Huang, Hanxiong Huang, Wenhao Huang, Xin Huang, Xingtao Huang, Yongbo Huang, Jiaqi Hui, Lei Huo, Wenju Huo, Cédric Huss, Safeer Hussain, Ara Ioannisian, Roberto Isocrate, Beatrice Jelmini, Kuo-Lun Jen, Ignacio Jeria, Xiaolu Ji, Xingzhao Ji, Huihui Jia, Junji Jia, Siyu Jian, Di Jiang, Xiaoshan Jiang, Ruyi Jin, Xiaoping Jing, Cécile Jollet, Jari Joutsenvaara, Sirichok Jungthawan, Leonidas Kalousis, Philipp Kampmann, Li Kang, Rebin Karaparambil, Narine Kazarian, Waseem Khan, Khanchai Khosonthongkee, Denis Korablev, Konstantin Kouzakov, Alexey Krasnoperov, Andre Kruth, Nikolay Kutovskiy, Pasi Kuusiniemi, Tobias Lachenmaier, Cecilia Landini, Sébastien Leblanc, Victor Lebrin, Frederic Lefevre, Ruiting Lei, Rupert Leitner, Jason Leung, Demin Li, Fei Li, Fule Li, Haitao Li, Huiling Li, Jiaqi Li, Mengzhao Li, Min Li, Nan Li, Qingjiang Li, Ruhui Li, Shanfeng Li, Tao Li, Weidong Li, Weiguo Li, Xiaomei Li, Xiaonan Li, Xinglong Li, Yi Li, Yufeng Li, Zhaohan Li, Zhibing Li, Ziyuan Li, Hao Liang, Jiajun Liao, Daniel Liebau, Ayut Limphirat, Sukit Limpijumnong, Guey-Lin Lin, Shengxin Lin, Tao Lin, Jiajie Ling, Ivano Lippi, Fang Liu, Haidong Liu, Hongbang Liu, Hongjuan Liu, Hongtao Liu, Hui Liu, Jianglai Liu, Jinchang Liu, Min Liu, Qian Liu, Qin Liu, Runxuan Liu, Shuangyu Liu, Shubin Liu, Shulin Liu, Xiaowei Liu, Xiwen Liu, Yan Liu, Yunzhe Liu, Alexey Lokhov, Paolo Lombardi, Claudio Lombardo, Kai Loo, Chuan Lu, Haoqi Lu, Jingbin Lu, Junguang Lu, Shuxiang Lu, Xiaoxu Lu, Bayarto Lubsandorzhiev, Sultim Lubsandorzhiev, Livia Ludhova, Fengjiao Luo, Guang Luo, Pengwei Luo, Shu Luo, Wuming Luo, Vladimir Lyashuk, Bangzheng Ma, Qiumei Ma, Si Ma, Xiaoyan Ma, Xubo Ma, Jihane Maalmi, Yury Malyshkin, Fabio Mantovani, Francesco Manzali, Xin Mao, Yajun Mao, Stefano M. Mari, Filippo Marini, Sadia Marium, Cristina Martellini, Gisele Martin-Chassard, Agnese Martini, Matthias Mayer, Davit Mayilyan, Ints Mednieks, Yue Meng, Anselmo Meregaglia, Emanuela Meroni, David Meyhöfer, Mauro Mezzetto, Jonathan Miller, Lino Miramonti, Paolo Montini, Michele Montuschi, Axel Müller, Massimiliano Nastasi, Dmitry V. Naumov, Elena Naumova, Diana Navas-Nicolas, Igor Nemchenok, Minh Thuan Nguyen Thi, Feipeng Ning, Zhe Ning, Hiroshi Nunokawa, Lothar Oberauer, Juan Pedro Ochoa-Ricoux, Alexander Olshevskiy, Domizia Orestano, Fausto Ortica, Rainer Othegraven, Hsiao-Ru Pan, Alessandro Paoloni, Sergio Parmeggiano, Yatian Pei, Nicomede Pelliccia, Anguo Peng, Haiping Peng, Frédéric Perrot, Pierre-Alexandre Petitjean, Fabrizio Petrucci, Oliver Pilarczyk, Luis Felipe Piñeres Rico, Artyom Popov, Pascal Poussot, Wathan Pratumwan, Ezio Previtali, Fazhi Qi, Ming Qi, Sen Qian, Xiaohui Qian, Zhen Qian, Hao Qiao, Zhonghua Qin, Shoukang Qiu, Muhammad Usman Rajput, Gioacchino Ranucci, Neill Raper, Alessandra Re, Henning Rebber, Abdel Rebii, Bin Ren, Jie Ren, Barbara Ricci, Markus Robens, Mathieu Roche, Narongkiat Rodphai, Aldo Romani, Bedřich Roskovec, Christian Roth, Xiangdong Ruan, Xichao Ruan, Saroj Rujirawat, Arseniy Rybnikov, Andrey Sadovsky, Paolo Saggese, Simone Sanfilippo, Anut Sangka, Nuanwan Sanguansak, Utane Sawangwit, Julia Sawatzki, Fatma Sawy, Michaela Schever, Cédric Schwab, Konstantin Schweizer, Alexandr Selyunin, Andrea Serafini, Giulio Settanta, Mariangela Settimo, Zhuang Shao, Vladislav Sharov, Arina Shaydurova, Jingyan Shi, Yanan Shi, Vitaly Shutov, Andrey Sidorenkov, Fedor Šimkovic, Chiara Sirignano, Jaruchit Siripak, Monica Sisti, Maciej Slupecki, Mikhail Smirnov, Oleg Smirnov, Thiago Sogo-Bezerra, Sergey Sokolov, Julanan Songwadhana, Boonrucksar Soonthornthum, Albert Sotnikov, Ondřej Šrámek, Warintorn Sreethawong, Achim Stahl, Luca Stanco, Konstantin Stankevich, Dušan Štefánik, Hans Steiger, Jochen Steinmann, Tobias Sterr, Matthias Raphael Stock, Virginia Strati, Alexander Studenikin, Shifeng Sun, Xilei Sun, Yongjie Sun, Yongzhao Sun, Narumon Suwonjandee, Michal Szelezniak, Jian Tang, Qiang Tang, Quan Tang, Xiao Tang, Alexander Tietzsch, Igor Tkachev, Tomas Tmej, Konstantin Treskov, Andrea Triossi, Giancarlo Troni, Wladyslaw Trzaska, Cristina Tuve, Nikita Ushakov, Johannes van den Boom, Stefan van Waasen, Guillaume Vanroyen, Nikolaos Vassilopoulos, Vadim Vedin, Giuseppe Verde, Maxim Vialkov, Benoit Viaud, Moritz Cornelius Vollbrecht, Cristina Volpe, Vit Vorobel, Dmitriy Voronin, Lucia Votano, Pablo Walker, Caishen Wang, Chung-Hsiang Wang, En Wang, Guoli Wang, Jian Wang, Jun Wang, Kunyu Wang, Lu Wang, Meifen Wang, Meng Wang, Ruiguang Wang, Siguang Wang, Wei Wang, Wenshuai Wang, Xi Wang, Xiangyue Wang, Yangfu Wang, Yaoguang Wang, Yi Wang, Yifang Wang, Yuanqing Wang, Yuman Wang, Zhe Wang, Zheng Wang, Zhimin Wang, Zongyi Wang, Muhammad Waqas, Apimook Watcharangkool, Lianghong Wei, Wei Wei, Wenlu Wei, Yadong Wei, Liangjian Wen, Christopher Wiebusch, Steven Chan-Fai Wong, Bjoern Wonsak, Diru Wu, Fangliang Wu, Qun Wu, Zhi Wu, Michael Wurm, Jacques Wurtz, Christian Wysotzki, Yufei Xi, Dongmei Xia, Xiaochuan Xie, Yuguang Xie, Zhangquan Xie, Zhizhong Xing, Benda Xu, Cheng Xu, Donglian Xu, Fanrong Xu, Hangkun Xu, Jilei Xu, Jing Xu, Meihang Xu, Yin Xu, Yu Xu, Baojun Yan, Taylor Yan, Wenqi Yan, Xiongbo Yan, Yupeng Yan, Anbo Yang, Changgen Yang, Chengfeng Yang, Huan Yang, Jie Yang, Lei Yang, Xiaoyu Yang, Yifan Yang, Haifeng Yao, Zafar Yasin, Jiaxuan Ye, Mei Ye, Ziping Ye, Ugur Yegin, Frédéric Yermia, Peihuai Yi, Na Yin, Xiangwei Yin, Zhengyun You, Boxiang Yu, Chiye Yu, Chunxu Yu, Hongzhao Yu, Miao Yu, Xianghui Yu, Zeyuan Yu, Zezhong Yu, Chengzhuo Yuan, Ying Yuan, Zhenxiong Yuan, Ziyi Yuan, Baobiao Yue, Noman Zafar, Andre Zambanini, Vitalii Zavadskyi, Shan Zeng, Tingxuan Zeng, Yuda Zeng, Liang Zhan, Aiqiang Zhang, Feiyang Zhang, Guoqing Zhang, Haiqiong Zhang, Honghao Zhang, Jiawen Zhang, Jie Zhang, Jin Zhang, Jingbo Zhang, Jinnan Zhang, Peng Zhang, Qingmin Zhang, Shiqi Zhang, Shu Zhang, Tao Zhang, Xiaomei Zhang, Xuantong Zhang, Xueyao Zhang, Yan Zhang, Yinhong Zhang, Yiyu Zhang, Yongpeng Zhang, Yuanyuan Zhang, Yumei Zhang, Zhenyu Zhang, Zhijian Zhang, Fengyi Zhao, Jie Zhao, Rong Zhao, Shujun Zhao, Tianchi Zhao, Dongqin Zheng, Hua Zheng, Minshan Zheng, Yangheng Zheng, Weirong Zhong, Jing Zhou, Li Zhou, Nan Zhou, Shun Zhou, Tong Zhou, Xiang Zhou, Jiang Zhu, Kangfu Zhu, Kejun Zhu, Zhihang Zhu, Bo Zhuang, Honglin Zhuang, Liang Zong, and Jiaheng Zou

Subjects
Neutrino Detectors and Telescopes (experiments), Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Abstract JUNO is a massive liquid scintillator detector with a primary scientific goal of determining the neutrino mass ordering by studying the oscillated anti-neutrino flux coming from two nuclear power plants at 53 km distance. The expected signal anti-neutrino interaction rate is only 60 counts per day (cpd), therefore a careful control of the background sources due to radioactivity is critical. In particular, natural radioactivity present in all materials and in the environment represents a serious issue that could impair the sensitivity of the experiment if appropriate countermeasures were not foreseen. In this paper we discuss the background reduction strategies undertaken by the JUNO collaboration to reduce at minimum the impact of natural radioactivity. We describe our efforts for an optimized experimental design, a careful material screening and accurate detector production handling, and a constant control of the expected results through a meticulous Monte Carlo simulation program. We show that all these actions should allow us to keep the background count rate safely below the target value of 10 Hz (i.e. ∼1 cpd accidental background) in the default fiducial volume, above an energy threshold of 0.7 MeV.

Published
2021
Full Text
View/download PDF

20. JUNO sensitivity to low energy atmospheric neutrino spectra

Author

Angel Abusleme, Thomas Adam, Shakeel Ahmad, Rizwan Ahmed, Sebastiano Aiello, Muhammad Akram, Fengpeng An, Guangpeng An, Qi An, Giuseppe Andronico, Nikolay Anfimov, Vito Antonelli, Tatiana Antoshkina, Burin Asavapibhop, João Pedro Athayde Marcondes de André, Didier Auguste, Andrej Babic, Wander Baldini, Andrea Barresi, Eric Baussan, Marco Bellato, Antonio Bergnoli, Enrico Bernieri, Thilo Birkenfeld, Sylvie Blin, David Blum, Simon Blyth, Anastasia Bolshakova, Mathieu Bongrand, Clément Bordereau, Dominique Breton, Augusto Brigatti, Riccardo Brugnera, Riccardo Bruno, Antonio Budano, Mario Buscemi, Jose Busto, Ilya Butorov, Anatael Cabrera, Hao Cai, Xiao Cai, Yanke Cai, Zhiyan Cai, Antonio Cammi, Agustin Campeny, Chuanya Cao, Guofu Cao, Jun Cao, Rossella Caruso, Cédric Cerna, Jinfan Chang, Yun Chang, Pingping Chen, Po-An Chen, Shaomin Chen, Xurong Chen, Yi-Wen Chen, Yixue Chen, Yu Chen, Zhang Chen, Jie Cheng, Yaping Cheng, Alexey Chetverikov, Davide Chiesa, Pietro Chimenti, Artem Chukanov, Gérard Claverie, Catia Clementi, Barbara Clerbaux, Selma Conforti Di Lorenzo, Daniele Corti, Salvatore Costa, Flavio Dal Corso, Olivia Dalager, Christophe De La Taille, Jiawei Deng, Zhi Deng, Ziyan Deng, Wilfried Depnering, Marco Diaz, Xuefeng Ding, Yayun Ding, Bayu Dirgantara, Sergey Dmitrievsky, Tadeas Dohnal, Dmitry Dolzhikov, Georgy Donchenko, Jianmeng Dong, Evgeny Doroshkevich, Marcos Dracos, Frédéric Druillole, Shuxian Du, Stefano Dusini, Martin Dvorak, Timo Enqvist, Heike Enzmann, Andrea Fabbri, Lukas Fajt, Donghua Fan, Lei Fan, Can Fang, Jian Fang, Wenxing Fang, Marco Fargetta, Dmitry Fedoseev, Vladko Fekete, Li-Cheng Feng, Qichun Feng, Richard Ford, Andrey Formozov, Amélie Fournier, Haonan Gan, Feng Gao, Alberto Garfagnini, Christoph Genster, Marco Giammarchi, Agnese Giaz, Nunzio Giudice, Maxim Gonchar, Guanghua Gong, Hui Gong, Oleg Gorchakov, Yuri Gornushkin, Alexandre Göttel, Marco Grassi, Christian Grewing, Vasily Gromov, Minghao Gu, Xiaofei Gu, Yu Gu, Mengyun Guan, Nunzio Guardone, Maria Gul, Cong Guo, Jingyuan Guo, Wanlei Guo, Xinheng Guo, Yuhang Guo, Paul Hackspacher, Caren Hagner, Ran Han, Yang Han, Muhammad Sohaib Hassan, Miao He, Wei He, Tobias Heinz, Patrick Hellmuth, Yuekun Heng, Rafael Herrera, Daojin Hong, YuenKeung Hor, Shaojing Hou, Yee Hsiung, Bei-Zhen Hu, Hang Hu, Jianrun Hu, Jun Hu, Shouyang Hu, Tao Hu, Zhuojun Hu, Chunhao Huang, Guihong Huang, Hanxiong Huang, Qinhua Huang, Wenhao Huang, Xin Huang, Xingtao Huang, Yongbo Huang, Jiaqi Hui, Lei Huo, Wenju Huo, Cédric Huss, Safeer Hussain, Antonio Insolia, Ara Ioannisian, Roberto Isocrate, Beatrice Jelmini, Kuo-Lun Jen, Ignacio Jeria, Xiaolu Ji, Xingzhao Ji, Huihui Jia, Junji Jia, Siyu Jian, Di Jiang, Xiaoshan Jiang, Ruyi Jin, Xiaoping Jing, Cécile Jollet, Sirichok Jungthawan, Leonidas Kalousis, Philipp Kampmann, Li Kang, Michael Karagounis, Narine Kazarian, Waseem Khan, Khanchai Khosonthongkee, Denis Korablev, Konstantin Kouzakov, Alexey Krasnoperov, Zinovy Krumshteyn, Andre Kruth, Nikolay Kutovskiy, Pasi Kuusiniemi, Tobias Lachenmaier, Cecilia Landini, Sébastien Leblanc, Victor Lebrin, Frederic Lefevre, Ruiting Lei, Rupert Leitner, Jason Leung, Demin Li, Fei Li, Fule Li, Haitao Li, Huiling Li, Jiaqi Li, Mengzhao Li, Min Li, Nan Li, Qingjiang Li, Ruhui Li, Shanfeng Li, Tao Li, Weidong Li, Weiguo Li, Xiaomei Li, Xiaonan Li, Xinglong Li, Yi Li, Yufeng Li, Zhaohan Li, Zhibing Li, Ziyuan Li, Hao Liang, Jingjing Liang, Daniel Liebau, Ayut Limphirat, Sukit Limpijumnong, Guey-Lin Lin, Shengxin Lin, Tao Lin, Jiajie Ling, Ivano Lippi, Fang Liu, Haidong Liu, Hongbang Liu, Hongjuan Liu, Hongtao Liu, Hui Liu, Jianglai Liu, Jinchang Liu, Min Liu, Qian Liu, Qin Liu, Runxuan Liu, Shuangyu Liu, Shubin Liu, Shulin Liu, Xiaowei Liu, Xiwen Liu, Yan Liu, Yunzhe Liu, Alexey Lokhov, Paolo Lombardi, Claudio Lombardo, Kai Loo, Chuan Lu, Haoqi Lu, Jingbin Lu, Junguang Lu, Shuxiang Lu, Xiaoxu Lu, Bayarto Lubsandorzhiev, Sultim Lubsandorzhiev, Livia Ludhova, Fengjiao Luo, Guang Luo, Pengwei Luo, Shu Luo, Wuming Luo, Vladimir Lyashuk, Bangzheng Ma, Qiumei Ma, Si Ma, Xiaoyan Ma, Xubo Ma, Jihane Maalmi, Yury Malyshkin, Fabio Mantovani, Francesco Manzali, Xin Mao, Yajun Mao, Stefano M. Mari, Filippo Marini, Sadia Marium, Cristina Martellini, Gisele Martin-Chassard, Agnese Martini, Davit Mayilyan, Ints Mednieks, Yue Meng, Anselmo Meregaglia, Emanuela Meroni, David Meyhöfer, Mauro Mezzetto, Jonathan Miller, Lino Miramonti, Salvatore Monforte, Paolo Montini, Michele Montuschi, Axel Müller, Pavithra Muralidharan, Massimiliano Nastasi, Dmitry V. Naumov, Elena Naumova, Diana Navas-Nicolas, Igor Nemchenok, Minh Thuan Nguyen Thi, Feipeng Ning, Zhe Ning, Hiroshi Nunokawa, Lothar Oberauer, Juan Pedro Ochoa-Ricoux, Alexander Olshevskiy, Domizia Orestano, Fausto Ortica, Rainer Othegraven, Hsiao-Ru Pan, Alessandro Paoloni, Nina Parkalian, Sergio Parmeggiano, Yatian Pei, Nicomede Pelliccia, Anguo Peng, Haiping Peng, Frédéric Perrot, Pierre-Alexandre Petitjean, Fabrizio Petrucci, Oliver Pilarczyk, Luis Felipe Piñeres Rico, Artyom Popov, Pascal Poussot, Wathan Pratumwan, Ezio Previtali, Fazhi Qi, Ming Qi, Sen Qian, Xiaohui Qian, Zhen Qian, Hao Qiao, Zhonghua Qin, Shoukang Qiu, Muhammad Usman Rajput, Gioacchino Ranucci, Neill Raper, Alessandra Re, Henning Rebber, Abdel Rebii, Bin Ren, Jie Ren, Taras Rezinko, Barbara Ricci, Markus Robens, Mathieu Roche, Narongkiat Rodphai, Aldo Romani, Bedřich Roskovec, Christian Roth, Xiangdong Ruan, Xichao Ruan, Saroj Rujirawat, Arseniy Rybnikov, Andrey Sadovsky, Paolo Saggese, Giuseppe Salamanna, Simone Sanfilippo, Anut Sangka, Nuanwan Sanguansak, Utane Sawangwit, Julia Sawatzki, Fatma Sawy, Michaela Schever, Jacky Schuler, Cédric Schwab, Konstantin Schweizer, Alexandr Selyunin, Andrea Serafini, Giulio Settanta, Mariangela Settimo, Zhuang Shao, Vladislav Sharov, Arina Shaydurova, Jingyan Shi, Yanan Shi, Vitaly Shutov, Andrey Sidorenkov, Fedor Šimkovic, Chiara Sirignano, Jaruchit Siripak, Monica Sisti, Maciej Slupecki, Mikhail Smirnov, Oleg Smirnov, Thiago Sogo-Bezerra, Sergey Sokolov, Julanan Songwadhana, Boonrucksar Soonthornthum, Albert Sotnikov, Ondřej Šrámek, Warintorn Sreethawong, Achim Stahl, Luca Stanco, Konstantin Stankevich, Dušan Štefánik, Hans Steiger, Jochen Steinmann, Tobias Sterr, Matthias Raphael Stock, Virginia Strati, Alexander Studenikin, Gongxing Sun, Shifeng Sun, Xilei Sun, Yongjie Sun, Yongzhao Sun, Narumon Suwonjandee, Michal Szelezniak, Jian Tang, Qiang Tang, Quan Tang, Xiao Tang, Alexander Tietzsch, Igor Tkachev, Tomas Tmej, Konstantin Treskov, Andrea Triossi, Giancarlo Troni, Wladyslaw Trzaska, Cristina Tuve, Nikita Ushakov, Johannes van den Boom, Stefan van Waasen, Guillaume Vanroyen, Nikolaos Vassilopoulos, Vadim Vedin, Giuseppe Verde, Maxim Vialkov, Benoit Viaud, Moritz Cornelius Vollbrecht, Cristina Volpe, Vit Vorobel, Dmitriy Voronin, Lucia Votano, Pablo Walker, Caishen Wang, Chung-Hsiang Wang, En Wang, Guoli Wang, Jian Wang, Jun Wang, Kunyu Wang, Lu Wang, Meifen Wang, Meng Wang, Ruiguang Wang, Siguang Wang, Wei Wang, Wenshuai Wang, Xi Wang, Xiangyue Wang, Yangfu Wang, Yaoguang Wang, Yi Wang, Yifang Wang, Yuanqing Wang, Yuman Wang, Zhe Wang, Zheng Wang, Zhimin Wang, Zongyi Wang, Muhammad Waqas, Apimook Watcharangkool, Lianghong Wei, Wei Wei, Wenlu Wei, Yadong Wei, Liangjian Wen, Christopher Wiebusch, Steven Chan-Fai Wong, Bjoern Wonsak, Diru Wu, Fangliang Wu, Qun Wu, Wenjie Wu, Zhi Wu, Michael Wurm, Jacques Wurtz, Christian Wysotzki, Yufei Xi, Dongmei Xia, Yuguang Xie, Zhangquan Xie, Zhizhong Xing, Benda Xu, Cheng Xu, Donglian Xu, Fanrong Xu, Hangkun Xu, Jilei Xu, Jing Xu, Meihang Xu, Yin Xu, Yu Xu, Baojun Yan, Taylor Yan, Wenqi Yan, Xiongbo Yan, Yupeng Yan, Anbo Yang, Changgen Yang, Huan Yang, Jie Yang, Lei Yang, Xiaoyu Yang, Yifan Yang, Haifeng Yao, Zafar Yasin, Jiaxuan Ye, Mei Ye, Ziping Ye, Ugur Yegin, Frédéric Yermia, Peihuai Yi, Na Yin, Xiangwei Yin, Zhengyun You, Boxiang Yu, Chiye Yu, Chunxu Yu, Hongzhao Yu, Miao Yu, Xianghui Yu, Zeyuan Yu, Zezhong Yu, Chengzhuo Yuan, Ying Yuan, Zhenxiong Yuan, Ziyi Yuan, Baobiao Yue, Noman Zafar, Andre Zambanini, Vitalii Zavadskyi, Shan Zeng, Tingxuan Zeng, Yuda Zeng, Liang Zhan, Aiqiang Zhang, Feiyang Zhang, Guoqing Zhang, Haiqiong Zhang, Honghao Zhang, Jiawen Zhang, Jie Zhang, Jingbo Zhang, Jinnan Zhang, Peng Zhang, Qingmin Zhang, Shiqi Zhang, Shu Zhang, Tao Zhang, Xiaomei Zhang, Xuantong Zhang, Xueyao Zhang, Yan Zhang, Yinhong Zhang, Yiyu Zhang, Yongpeng Zhang, Yuanyuan Zhang, Yumei Zhang, Zhenyu Zhang, Zhijian Zhang, Fengyi Zhao, Jie Zhao, Rong Zhao, Shujun Zhao, Tianchi Zhao, Dongqin Zheng, Hua Zheng, Minshan Zheng, Yangheng Zheng, Weirong Zhong, Jing Zhou, Li Zhou, Nan Zhou, Shun Zhou, Tong Zhou, Xiang Zhou, Jiang Zhu, Kejun Zhu, Zhihang Zhu, Bo Zhuang, Honglin Zhuang, Liang Zong, Jiaheng Zou, and The JUNO Collaboration

Subjects
Astrophysics, QB460-466, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Abstract Atmospheric neutrinos are one of the most relevant natural neutrino sources that can be exploited to infer properties about cosmic rays and neutrino oscillations. The Jiangmen Underground Neutrino Observatory (JUNO) experiment, a 20 kton liquid scintillator detector with excellent energy resolution is currently under construction in China. JUNO will be able to detect several atmospheric neutrinos per day given the large volume. A study on the JUNO detection and reconstruction capabilities of atmospheric $$\nu _e$$ ν e and $$\nu _\mu $$ ν μ fluxes is presented in this paper. In this study, a sample of atmospheric neutrino Monte Carlo events has been generated, starting from theoretical models, and then processed by the detector simulation. The excellent timing resolution of the 3” PMT light detection system of JUNO detector and the much higher light yield for scintillation over Cherenkov allow to measure the time structure of the scintillation light with very high precision. Since $$\nu _e$$ ν e and $$\nu _\mu $$ ν μ interactions produce a slightly different light pattern, the different time evolution of light allows to discriminate the flavor of primary neutrinos. A probabilistic unfolding method has been used, in order to infer the primary neutrino energy spectrum from the detector experimental observables. The simulated spectrum has been reconstructed between 100 MeV and 10 GeV, showing a great potential of the detector in the atmospheric low energy region.

Published
2021
Full Text
View/download PDF

21. Metabolomic comparison followed by cross-validation of enzyme-linked immunosorbent assay to reveal potential biomarkers of diabetic retinopathy in Chinese with type 2 diabetes

Author

Zongyi Wang, Jiyang Tang, Enzhong Jin, Chi Ren, Siying Li, Linqi Zhang, Yusheng Zhong, Yu Cao, Jianmin Wang, Wei Zhou, Mingwei Zhao, Lvzhen Huang, and Jinfeng Qu

Subjects
biomarker, diabetic retinopathy, enzyme-linked immunosorbent assay, metabolomics, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

PurposeTo identify the biomarkers in the critical period of development in diabetic retinopathy (DR) in Chinese with type 2 diabetes using targeted and untargeted metabolomics, and to explore the feasibility of their clinical applicationMethodsThis case-control study described the differential metabolites between 83 Chinese type 2 diabetes mellitus (T2DM) samples with disease duration ≥ 10 years and 27 controls matched cases. Targeted metabolomics using high-resolution mass spectrometry with liquid chromatography was performed on plasma samples of subjects. The results were compared to our previous untargeted metabolomics study and ELISA was performed to validate the mutual differential metabolites of targeted and untargeted metabolomics on plasma. Multiple linear regression analyses were performed to adjust for the significance of different metabolites between groups.ResultMean age of the subjects was 66.3 years and mean T2DM duration was 16.5 years. By cross-validating with results from previous untargeted metabolomic assays, we found that L-Citrulline (Cit), indoleacetic acid (IAA), 1-methylhistidine (1-MH), phosphatidylcholines (PCs), hexanoylcarnitine, chenodeoxycholic acid (CDCA) and eicosapentaenoic acid (EPA) were the most distinctive metabolites biomarkers to distinguish the severity of DR for two different metabolomic approaches in our study. We mainly found that samples in the DR stage showed lower serum level of Cit and higher serum level of IAA compared with samples in the T2DM stage, while during the progression of diabetic retinopathy, the serum levels of CDCA and EPA in PDR stage were significantly lower than NPDR stage. Among them, 4 differential key metabolites including Cit, IAA, CDCA and EPA were confirmed with ELISA.ConclusionThis is the first study to compare the results of targeted and untargeted metabolomics via liquid chromatography-mass spectrometry to find the serum biomarkers which could reflect the metabolic variations among different stages of DR in Chinese. The progression of DR in Chinese at different critical stages was related to the serum levels of specific differential metabolites, of which there is a significant correlation between DR progression and increased IAA and decreased Cit, hexanoylcarnitine, CDCA, and EPA. However, larger studies are needed to confirm our results. Based on this study, it could be inferred that the accuracy of targeted metabolomics for metabolite expression in serum is to some extent higher than that of untargeted metabolomics.

Published
2022
Full Text
View/download PDF

22. Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians

Author

Zongyi Wang, Jiyang Tang, Enzhong Jin, Yusheng Zhong, Linqi Zhang, Xinyao Han, Jia Liu, Yong Cheng, Jing Hou, Xuan Shi, Huijun Qi, Tong Qian, Li Yuan, Xianru Hou, Hong Yin, Jianhong Liang, Mingwei Zhao, Lvzhen Huang, and Jinfeng Qu

Subjects
Type 2 diabetes, proliferative diabetic retinopathy, non-proliferative diabetic retinopathy, metabolomics, untargeted metabolomics, metabolic profiling, Biology (General), QH301-705.5
Abstract

Purpose: To reveal molecular mechanisms of diabetic retinopathy (DR) in Asians and facilitate the identification of new therapeutic targets through untargeted metabolomics. To determine the differences in serum metabolites and metabolic pathways between different stages of diabetic retinopathy in patients with type 2 diabetic mellitus (T2DM) and proliferative DR (PDR) and non-proliferative DR (NPDR) and identify differential metabolites between T2DM and DR (NPDR and PDR) patients.Methods: This prospective observational registration study described the differential metabolites between 45 T2DM patients and 15 control cases with no significant differences in clinical characteristics. Their biospecimens and clinical information were collected and recorded in their medical reports. DR phenotypes of the subjects were verified by retina specialists. Serum metabolites were analyzed using high-resolution mass spectrometry with liquid chromatography. Untargeted metabolomics was performed on serum samples from 15 T2DM patients, 15 non-proliferative diabetic retinopathy patients, 15 proliferative diabetic retinopathy patients, and 15 diabetic controls. Discriminatory metabolic features were identified through partial least squares discriminant analysis (PLS-DA), hierarchical clustering analysis (HCA), and generalized linear regression models.Result: Through untargeted metabolomics, 931 features (523 in positive and 408 in negative modes) with 102 common metabolites highly relevant to the presence of DR were detected. In the adjusted analysis, 67 metabolic features differed significantly between T2DM and NPDR patients. Pathway analysis revealed alterations in metabolisms of amino acids and fatty acids. Glutamate, phosphatidylcholine, and 13-hydroperoxyoctadeca-9,11-dienoic acid (13-PHODE) were key contributors to these pathway differences. A total of 171 features distinguished PDR patients from T2DM patients, and pathway analysis revealed alterations in amino acid metabolism, fatty acid metabolism, nitrogen metabolism, and tricarboxylic acid cycle. Aspartate, glutamate, glutamine, ornithine, N-acetyl-l-glutamate, N-acetyl-l-aspartate, citrate, succinate, N-(L-arginino)succinate, 2-oxoglutarate, 13-hydroperoxyoctadeca-9,11-dienoic acid, methionine, lysine, threonine, phenylalanine, N(pi)-methyl-l-histidine, phosphatidylcholine, and linoleate were major contributors to the pathway differences. Between NPDR patients and PDR patients, there were 79 significant differential metabolites. Enrichment pathway analysis showed changes in amino acid metabolism, fatty acid metabolism, pantothenate, and CoA biosynthesis. Aspartate, glutamine, N-acetyl-l-glutamate, N-acetyl-l-aspartate, pantothenate, dihomo-gamma-linolenate, docosahexaenoic acid, and icosapentaenoic acid were key factors for the differences of these pathways.Conclusion: This study demonstrated that the pathways of arginine biosynthesis metabolism, linoleic acid metabolism, alanine, aspartate, and glutamate metabolism, as well as d-glutamine and d-glutamate metabolism, were dysregulated in DR patients of the Asian population. Increased levels of glutamate, aspartate, glutamine, N-acetyl-l-glutamate, and N-acetyl-l-aspartate and decreased levels of dihomo-gamma-linolenate, docosahexaenoic, and icosapentaenoic were considered as the metabolic profile that could distinguish PDR from NPDR in Asians. Phosphatidylcholine and 13-PHODE were identified as two major novel metabolite markers in advanced stages of DR in our study.

Published
2022
Full Text
View/download PDF

23. MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma

Author

Mengkai Yang, Tao Zhang, Yangfeng Zhang, Xiaojun Ma, Jing Han, Ke Zeng, Yafei Jiang, Zongyi Wang, Zhuoying Wang, Jing Xu, Yingqi Hua, Zhengdong Cai, and Wei Sun

Subjects
MYLK4, Osteosarcoma, Epidermal growth factor receptor, Growth, Metastasis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Osteosarcoma (OS) is the most common primary bone cancer in adolescents and lung metastasis is the leading cause of death in patients with OS. However, the molecular mechanisms that promote OS growth and metastasis remain unknown. Methods We investigated the expression of myosin light chain kinase family members between metastasis and non-metastasis patients in the TARGET database and ensured that only myosin light chain kinase family member 4 (MYLK4) had higher expression in metastatic osteosarcoma patients. Then we confirmed the results by immunohistochemistry (IHC) and Western blotting (WB) of OS tissues. The effect of MYLK4 on the metastasis and proliferation of OS cells was investigated by wound healing, Transwell and colony-formation assays. Mass spectrum analysis was used to ensure the new binding protein of MYLK4. Tissue microarrays analysis was used to show the correlation between MYLK4 and pEGFR (Y1068). A series of in vivo experiments were conducted to reveal the mechanisms by which MYLK4 modulated the metastasis and proliferation of OS. Results Myosin Light Chain Kinase Family Member 4 (MYLK4) was significantly upregulated in metastatic human OS tissues. Growth and metastasis of OS could be accelerated by MYLK4 overexpression, whereas silencing MYLK4 expression resulted in decreased cell growth and metastasis. Mechanistically, mass spectrum analysis showed that MYLK4 interacted with the epidermal growth factor receptor (EGFR) in osteosarcoma cells and promoted growth and metastasis via the EGFR signaling pathway. Tissue microarrays analysis also showed that MYLK4 expression had a positive correlation with the expression of pEGFR (Y1068). Moreover, the EGFR inhibitor gefitinib could partially reverse the effect of cell proliferation and metastasis caused by MYLK4 overexpression. Importantly, the combination of MYLK4 and EGFR inhibitors had synergistic effects on growth and metastasis of OS in vitro and in vivo. Conclusion Our results indicate that MYLK4 promotes OS growth and metastasis by activating the EGFR signaling pathway and can be a novel therapeutic target for the treatment of OS patients.

Published
2021
Full Text
View/download PDF

24. Calibration strategy of the JUNO experiment

Author

The JUNO collaboration, Angel Abusleme, Thomas Adam, Shakeel Ahmad, Rizwan Ahmed, Sebastiano Aiello, Muhammad Akram, Fengpeng An, Guangpeng An, Qi An, Giuseppe Andronico, Nikolay Anfimov, Vito Antonelli, Tatiana Antoshkina, Burin Asavapibhop, João Pedro Athayde Marcondes de André, Didier Auguste, Andrej Babic, Wander Baldini, Andrea Barresi, Eric Baussan, Marco Bellato, Antonio Bergnoli, Enrico Bernieri, Thilo Birkenfeld, Sylvie Blin, David Blum, Simon Blyth, Anastasia Bolshakova, Mathieu Bongrand, Clément Bordereau, Dominique Breton, Augusto Brigatti, Riccardo Brugnera, Riccardo Bruno, Antonio Budano, Mario Buscemi, Jose Busto, Ilya Butorov, Anatael Cabrera, Hao Cai, Xiao Cai, Yanke Cai, Zhiyan Cai, Antonio Cammi, Agustin Campeny, Chuanya Cao, Guofu Cao, Jun Cao, Rossella Caruso, Cédric Cerna, Jinfan Chang, Yun Chang, Pingping Chen, Po-An Chen, Shaomin Chen, Shenjian Chen, Xurong Chen, Yi-Wen Chen, Yixue Chen, Yu Chen, Zhang Chen, Jie Cheng, Yaping Cheng, Davide Chiesa, Pietro Chimenti, Artem Chukanov, Anna Chuvashova, Gérard Claverie, Catia Clementi, Barbara Clerbaux, Selma Conforti Di Lorenzo, Daniele Corti, Salvatore Costa, Flavio Dal Corso, Olivia Dalager, Christophe De La Taille, Jiawei Deng, Zhi Deng, Ziyan Deng, Wilfried Depnering, Marco Diaz, Xuefeng Ding, Yayun Ding, Bayu Dirgantara, Sergey Dmitrievsky, Tadeas Dohnal, Georgy Donchenko, Jianmeng Dong, Damien Dornic, Evgeny Doroshkevich, Marcos Dracos, Frédéric Druillole, Shuxian Du, Stefano Dusini, Martin Dvorak, Timo Enqvist, Heike Enzmann, Andrea Fabbri, Lukas Fajt, Donghua Fan, Lei Fan, Can Fang, Jian Fang, Marco Fargetta, Anna Fatkina, Dmitry Fedoseev, Vladko Fekete, Li-Cheng Feng, Qichun Feng, Richard Ford, Andrey Formozov, Amélie Fournier, Haonan Gan, Feng Gao, Alberto Garfagnini, Alexandre Göttel, Christoph Genster, Marco Giammarchi, Agnese Giaz, Nunzio Giudice, Franco Giuliani, Maxim Gonchar, Guanghua Gong, Hui Gong, Oleg Gorchakov, Yuri Gornushkin, Marco Grassi, Christian Grewing, Vasily Gromov, Minghao Gu, Xiaofei Gu, Yu Gu, Mengyun Guan, Nunzio Guardone, Maria Gul, Cong Guo, Jingyuan Guo, Wanlei Guo, Xinheng Guo, Yuhang Guo, Paul Hackspacher, Caren Hagner, Ran Han, Yang Han, Muhammad Hassan, Miao He, Wei He, Tobias Heinz, Patrick Hellmuth, Yuekun Heng, Rafael Herrera, Daojin Hong, YuenKeung Hor, Shaojing Hou, Yee Hsiung, Bei-Zhen Hu, Hang Hu, Jianrun Hu, Jun Hu, Shouyang Hu, Tao Hu, Zhuojun Hu, Chunhao Huang, Guihong Huang, Hanxiong Huang, Qinhua Huang, Wenhao Huang, Xingtao Huang, Yongbo Huang, Jiaqi Hui, Lei Huo, Wenju Huo, Cédric Huss, Safeer Hussain, Antonio Insolia, Ara Ioannisian, Roberto Isocrate, Beatrice Jelmini, Kuo-Lun Jen, Xiaolu Ji, Xingzhao Ji, Huihui Jia, Junji Jia, Siyu Jian, Di Jiang, Xiaoshan Jiang, Ruyi Jin, Xiaoping Jing, Cécile Jollet, Jari Joutsenvaara, Sirichok Jungthawan, Leonidas Kalousis, Philipp Kampmann, Li Kang, Michael Karagounis, Narine Kazarian, Amir Khan, Waseem Khan, Khanchai Khosonthongkee, Patrick Kinz, Denis Korablev, Konstantin Kouzakov, Alexey Krasnoperov, Svetlana Krokhaleva, Zinovy Krumshteyn, Andre Kruth, Nikolay Kutovskiy, Pasi Kuusiniemi, Tobias Lachenmaier, Cecilia Landini, Sébastien Leblanc, Victor Lebrin, Frederic Lefevre, Ruiting Lei, Rupert Leitner, Jason Leung, Demin Li, Fei Li, Fule Li, Haitao Li, Huiling Li, Jiaqi Li, Jin Li, Kaijie Li, Mengzhao Li, Nan Li, Qingjiang Li, Ruhui Li, Shanfeng Li, Shuaijie Li, Tao Li, Weidong Li, Weiguo Li, Xiaomei Li, Xiaonan Li, Xinglong Li, Yi Li, Yufeng Li, Zhibing Li, Ziyuan Li, Hao Liang, Jingjing Liang, Daniel Liebau, Ayut Limphirat, Sukit Limpijumnong, Guey-Lin Lin, Shengxin Lin, Tao Lin, Jiajie Ling, Ivano Lippi, Fang Liu, Haidong Liu, Hongbang Liu, Hongjuan Liu, Hongtao Liu, Hu Liu, Hui Liu, Jianglai Liu, Jinchang Liu, Min Liu, Qian Liu, Qin Liu, Runxuan Liu, Shuangyu Liu, Shubin Liu, Shulin Liu, Xiaowei Liu, Yan Liu, Alexey Lokhov, Paolo Lombardi, Claudio Lombardo, Kai Loo, Chuan Lu, Haoqi Lu, Jingbin Lu, Junguang Lu, Shuxiang Lu, Xiaoxu Lu, Bayarto Lubsandorzhiev, Sultim Lubsandorzhiev, Livia Ludhova, Fengjiao Luo, Guang Luo, Pengwei Luo, Shu Luo, Wuming Luo, Vladimir Lyashuk, Qiumei Ma, Si Ma, Xiaoyan Ma, Xubo Ma, Jihane Maalmi, Yury Malyshkin, Fabio Mantovani, Francesco Manzali, Xin Mao, Yajun Mao, Stefano M. Mari, Filippo Marini, Sadia Marium, Cristina Martellini, Gisele Martin-Chassard, Agnese Martini, Davit Mayilyan, Axel Müller, Ints Mednieks, Yue Meng, Anselmo Meregaglia, Emanuela Meroni, David Meyhöfer, Mauro Mezzetto, Jonathan Miller, Lino Miramonti, Salvatore Monforte, Paolo Montini, Michele Montuschi, Nikolay Morozov, Waqas Muhammad, Pavithra Muralidharan, Massimiliano Nastasi, Dmitry V. Naumov, Elena Naumova, Diana Navas-Nicolas, Igor Nemchenok, Feipeng Ning, Zhe Ning, Hiroshi Nunokawa, Lothar Oberauer, Juan Pedro Ochoa-Ricoux, Alexander Olshevskiy, Domizia Orestano, Fausto Ortica, Hsiao-Ru Pan, Alessandro Paoloni, Nina Parkalian, Sergio Parmeggiano, Teerapat Payupol, Yatian Pei, Nicomede Pelliccia, Anguo Peng, Haiping Peng, Frédéric Perrot, Pierre-Alexandre Petitjean, Fabrizio Petrucci, Luis Felipe Piñeres Rico, Oliver Pilarczyk, Artyom Popov, Pascal Poussot, Wathan Pratumwan, Ezio Previtali, Fazhi Qi, Ming Qi, Sen Qian, Xiaohui Qian, Hao Qiao, Zhonghua Qin, Shoukang Qiu, Muhammad Rajput, Gioacchino Ranucci, Neill Raper, Alessandra Re, Henning Rebber, Abdel Rebii, Bin Ren, Jie Ren, Taras Rezinko, Barbara Ricci, Markus Robens, Mathieu Roche, Narongkiat Rodphai, Aldo Romani, Bedřich Roskovec, Christian Roth, Xiangdong Ruan, Xichao Ruan, Saroj Rujirawat, Arseniy Rybnikov, Andrey Sadovsky, Paolo Saggese, Giuseppe Salamanna, Simone Sanfilippo, Anut Sangka, Nuanwan Sanguansak, Utane Sawangwit, Julia Sawatzki, Fatma Sawy, Michaela Schever, Jacky Schuler, Cédric Schwab, Konstantin Schweizer, Dmitry Selivanov, Alexandr Selyunin, Andrea Serafini, Giulio Settanta, Mariangela Settimo, Zhuang Shao, Vladislav Sharov, Jingyan Shi, Vitaly Shutov, Andrey Sidorenkov, Fedor Šimkovic, Chiara Sirignano, Jaruchit Siripak, Monica Sisti, Maciej Slupecki, Mikhail Smirnov, Oleg Smirnov, Thiago Sogo-Bezerra, Julanan Songwadhana, Boonrucksar Soonthornthum, Albert Sotnikov, Ondrej Sramek, Warintorn Sreethawong, Achim Stahl, Luca Stanco, Konstantin Stankevich, Dušan Štefánik, Hans Steiger, Jochen Steinmann, Tobias Sterr, Matthias Raphael Stock, Virginia Strati, Alexander Studenikin, Gongxing Sun, Shifeng Sun, Xilei Sun, Yongjie Sun, Yongzhao Sun, Narumon Suwonjandee, Michal Szelezniak, Jian Tang, Qiang Tang, Quan Tang, Xiao Tang, Alexander Tietzsch, Igor Tkachev, Tomas Tmej, Konstantin Treskov, Andrea Triossi, Giancarlo Troni, Wladyslaw Trzaska, Cristina Tuve, Stefan van Waasen, Johannes van den Boom, Guillaume Vanroyen, Nikolaos Vassilopoulos, Vadim Vedin, Giuseppe Verde, Maxim Vialkov, Benoit Viaud, Cristina Volpe, Vit Vorobel, Lucia Votano, Pablo Walker, Caishen Wang, Chung-Hsiang Wang, En Wang, Guoli Wang, Jian Wang, Jun Wang, Kunyu Wang, Lu Wang, Meifen Wang, Meng Wang, Ruiguang Wang, Siguang Wang, Wei Wang, Wenshuai Wang, Xi Wang, Xiangyue Wang, Yangfu Wang, Yaoguang Wang, Yi Wang, Yifang Wang, Yuanqing Wang, Yuman Wang, Zhe Wang, Zheng Wang, Zhimin Wang, Zongyi Wang, Apimook Watcharangkool, Lianghong Wei, Wei Wei, Yadong Wei, Liangjian Wen, Christopher Wiebusch, Steven Chan-Fai Wong, Bjoern Wonsak, Diru Wu, Fangliang Wu, Qun Wu, Wenjie Wu, Zhi Wu, Michael Wurm, Jacques Wurtz, Christian Wysotzki, Yufei Xi, Dongmei Xia, Mengjiao Xiao, Yuguang Xie, Zhangquan Xie, Zhizhong Xing, Benda Xu, Cheng Xu, Donglian Xu, Fanrong Xu, Jilei Xu, Jing Xu, Meihang Xu, Yin Xu, Yu Xu, Baojun Yan, Xiongbo Yan, Yupeng Yan, Anbo Yang, Changgen Yang, Huan Yang, Jie Yang, Lei Yang, Xiaoyu Yang, Yifan Yang, Haifeng Yao, Zafar Yasin, Jiaxuan Ye, Mei Ye, Ziping Ye, Ugur Yegin, Frédéric Yermia, Peihuai Yi, Xiangwei Yin, Zhengyun You, Boxiang Yu, Chiye Yu, Chunxu Yu, Hongzhao Yu, Miao Yu, Xianghui Yu, Zeyuan Yu, Chengzhuo Yuan, Ying Yuan, Zhenxiong Yuan, Ziyi Yuan, Baobiao Yue, Noman Zafar, Andre Zambanini, Shan Zeng, Tingxuan Zeng, Yuda Zeng, Liang Zhan, Feiyang Zhang, Guoqing Zhang, Haiqiong Zhang, Honghao Zhang, Jiawen Zhang, Jie Zhang, Jingbo Zhang, Peng Zhang, Qingmin Zhang, Shiqi Zhang, Shu Zhang, Tao Zhang, Xiaomei Zhang, Xuantong Zhang, Yan Zhang, Yinhong Zhang, Yiyu Zhang, Yongpeng Zhang, Yuanyuan Zhang, Yumei Zhang, Zhenyu Zhang, Zhijian Zhang, Fengyi Zhao, Jie Zhao, Rong Zhao, Shujun Zhao, Tianchi Zhao, Dongqin Zheng, Hua Zheng, Minshan Zheng, Yangheng Zheng, Weirong Zhong, Jing Zhou, Li Zhou, Nan Zhou, Shun Zhou, Xiang Zhou, Jiang Zhu, Kejun Zhu, Honglin Zhuang, Liang Zong, and Jiaheng Zou

Subjects
Neutrino Detectors and Telescopes (experiments), Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Abstract We present the calibration strategy for the 20 kton liquid scintillator central detector of the Jiangmen Underground Neutrino Observatory (JUNO). By utilizing a comprehensive multiple-source and multiple-positional calibration program, in combination with a novel dual calorimetry technique exploiting two independent photosensors and readout systems, we demonstrate that the JUNO central detector can achieve a better than 1% energy linearity and a 3% effective energy resolution, required by the neutrino mass ordering determination.

Published
2021
Full Text
View/download PDF

25. Degradation of subchondral bone collagen in the weight-bearing area of femoral head is associated with osteoarthritis and osteonecrosis

Author

Zongyi Wu, Bingzhang Wang, Jiahao Tang, Bingli Bai, Sheji Weng, Zhongjie Xie, Zijian Shen, Deyi Yan, Liang Chen, Jingdong Zhang, and Lei Yang

Subjects
Collagen fibers, Subchondral bone, Femoral head, Osteoarthritis, Osteonecrosis, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background The aim of the study was to evaluate the change of subchondral bone collagen and trabecular bone in the weight-bearing area of femoral head from patients with osteoarthritis (OA) or osteonecrosis of femoral head (ONFH), and discuss the effect of collagen degradation on OA and ONFH. Methods Femoral heads from patients with femoral neck fracture (FNF) were collected as control group. All collected samples were divided into OA group (N = 10), ONFH group (N = 10), and FNF group (N = 10). Differences of subchondral bone collagen were compared through scanning electron microscope (SEM) observation, immunohistochemistry staining, and Masson’s trichrome staining. Alteration of subchondral bone was displayed through hematoxylin and eosin (H&E) staining and gross morphology. Results SEM results showed that collagen fibers in OA and ONFH group appeared to be thinner, rougher, sparser, and more wizened. Immunohistochemistry and Masson’s trichrome staining results demonstrated that the content of collagen fibers in the OA and ONFH group was obviously less than the FNF group. H&E staining results showed that trabecular bone in OA and ONFH group appeared to be thinner and ruptured. Gross morphology results showed that the degeneration and destruction of cartilage and subchondral bone in OA and ONFH group were severer than FNF group. The characteristics mentioned above in ONFH group were more apparent than OA group. Conclusions This study revealed that degradation of collagen fibers from subchondral bone in the weight-bearing area of femoral head was associated with OA and ONFH, which may help to find new therapeutic strategies of the diseases.

Published
2020
Full Text
View/download PDF

26. Fatigue Life Prediction of Notched Details Using SWT Model and LEFM-Based Approach

Author

Rui Hao, Zongyi Wen, Haohui Xin, and Weiwei Lin

Subjects
fatigue, XFEM, numerical simulation, fatigue life prediction, UDMGINI, Technology, Electrical engineering. Electronics. Nuclear engineering, TK1-9971, Engineering (General). Civil engineering (General), TA1-2040, Microscopy, QH201-278.5, Descriptive and experimental mechanics, QC120-168.85
Abstract

The fatigue crack initiation life of unwelded steel components accounts for the majority of the total fatigue life, and the accurate prediction of it is of vital importance. In this study, a numerical model utilizing the extended finite element method (XFEM) and Smith–Watson–Topper (SWT) model is established to predict the fatigue crack initiation life of notched details extensively used in orthotropic steel deck bridges. Using the user subroutine UDMGINI in Abaqus, a new algorithm was proposed to calculate the damage parameter of SWT under high-cycle fatigue loads. The virtual crack-closure technique (VCCT) was introduced to monitor crack propagation. Nineteen tests were performed, and the results were used to validate the proposed algorithm and XFEM model. The simulation results show that the proposed XFEM model with UDMGINI and VCCT can reasonably predict the fatigue lives of the notched specimens within the regime of high-cycle fatigue with a load ratio of 0.1. The error for the prediction of fatigue initiation life ranges from −27.5% to 41.1%, and the prediction of total fatigue life has a good agreement with the experimental results with a scatter factor of around 2.

Published
2023
Full Text
View/download PDF

27. Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

Author

Zongyi Wei, Yuxin Zhou, Rongjie Wang, Jin Wang, and Zhenhua Chen

Subjects
aptamers, smart ligands, targeted, drug delivery, cancer therapy, Pharmacy and materia medica, RS1-441
Abstract

Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system is usually composed of a nanocarrier and a targeting component. The targeting component is called a “ligand”. Aptamers have high target affinity and specificity, which are identified as attractive and promising ligands. Therefore, aptamers have potential application in the development of smart targeting systems. For instance, aptamers are able to efficiently recognize tumor markers such as nucleolin, mucin, and epidermal growth factor receptor (EGFR). Besides, aptamers can also identify glycoproteins on the surface of tumor cells. Thus, the aptamer-mediated targeted drug delivery system has received extensive attention in the application of cancer therapy. This article reviews the application of aptamers as smart ligands for targeted drug delivery in cancer therapy. Special interest is focused on aptamers as smart ligands, aptamer-conjugated nanocarriers, aptamer targeting strategy for tumor microenvironment (TME), and aptamers that are specified to crucial cancer biomarkers for targeted drug delivery.

Published
2022
Full Text
View/download PDF

28. Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

Author

Yafei Jiang, Gangyang Wang, Haoran Mu, Xiaojun Ma, Zhuoying Wang, Yu Lv, Tao Zhang, Jing Xu, Jinzeng Wang, Yunqi Li, Jing Han, Mengkai Yang, Zongyi Wang, Ke Zeng, Xinmeng Jin, Song Xue, Mingzhu Yin, Wei Sun, Yingqi Hua, and Zhengdong Cai

Subjects
osteosarcoma, BRD4, NHWD-870, chemosensitivity, PDX 3, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Osteosarcoma is the most common primary malignant bone tumor, and there are few ideal clinically available drugs. The bromodomain and extraterminal domain (BET) protein is an emerging target for aggressive cancer, but therapies targeting the BET in osteosarcoma have been unsuccessful in clinical trials to date, and further exploration of specific BET inhibitors is of great significance. In our study, we demonstrated that NHWD-870, a potent BET inhibitor in a phase I clinical trial, significantly inhibited tumor proliferation and promoted cell apoptosis by reversing the oncogenic signature in osteosarcoma. More importantly, we identified NHWD-870 impeded binding of BRD4 to the promoter of GP130 leading to diminished activation of JAK/STAT3 signaling pathway. Furthermore, GP130 knockdown significantly sensitizes the chemosensitivity in vitro. In OS cell-derived xenografts, NHWD-870 effectively inhibited the growth of osteosarcoma. Beyond that, NHWD-870 effectively inhibited the differentiation and maturation of precursor osteoclasts in vitro and attenuated osteoclast-mediated bone loss in vivo. Finally, we confirmed the efficacy of synthetic lethal effects of NHWD-870 and cisplatin in antagonizing osteosarcoma in a preclinical PDX model. Taken together, these findings demonstrate that NHWD-870, as an effective BET inhibitor, may be a potential candidate for osteosarcoma intervention linked to its STAT3 signaling inhibitory activity. In addition, NHWD-870 appears to be a promising therapeutic strategy for bone-associated tumors, as it interferes with the vicious cycle of tumor progression and bone destruction.

Published
2021
Full Text
View/download PDF

29. PolishNet-2d and PolishNet-3d: Deep Learning-Based Workpiece Recognition

Author

Fuqiang Liu and Zongyi Wang

Subjects
Deep learning, 2d workpiece detection, 3d workpiece recognition, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

In recent years, there have been many deep learning research projects based on two-dimensional object detection and three-dimensional point cloud recognition. However, relatively few of these combine the two, and the number of projects based on a three-dimensional workpiece recognition method for the industrial field is even fewer. In this paper, to perform the recognition task for polishing workpieces in manufacturing, we use RGB-D images as input, and propose our designed PolishNet-2d for two-dimensional workpiece detection and our designed PolishNet-3d for three-dimensional workpiece recognition. The two deep neural networks are employed together in series to first detect and then recognize polishing workpieces in an industrial environment. For this paper, a large number of experiments have been carried out on deep learning datasets of polishing workpieces. These datasets were created by us to contain diverse combinations of real and simulated workpieces in real and simulated industrial environments. The contributions of this paper are as follows: (1) A rotation parameter learning network is proposed and a two-dimensional workpiece detection neural network, named PolishNet-2d, which was constructed by integrating our designed algorithms with the backbone networks ResNet101 and region proposal network (RPN), is introduced; (2) A hierarchical feature extraction network is proposed and a three-dimensional workpiece recognition neural network, named PolishNet-3d, which was constructed by integrating our designed algorithms with the backbone network PointNet, is introduced; (3) PolishNet-2d and PolishNet-3d are employed in series, with the detection output of PolishNet-2d being used as the input for PolishNet-3d for its recognition tasks: the workpiece regions are detected in the RGB image; the workpiece point cloud is segmented in the corresponding regions in the depth image, and lastly the segmented point cloud is placed into PolishNet-3d to identify the workpiece; (4) For the experiments in this paper, datasets containing rich and diverse data types of polishing workpieces for industrial fields have been constructed; (5) Numerous experimental results on polishing workpiece datasets show that the conjunction of PolishNet-2d and PolishNet-3d can achieve exemplary recognition results on polishing workpiece datasets.

Published
2019
Full Text
View/download PDF

30. CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma

Author

Zongyi Wang, Fei Yin, Jing Xu, Tao Zhang, Gangyang Wang, Ming Mao, Zhuoying Wang, Wei Sun, Jing Han, Mengkai Yang, Yafei Jiang, Yingqi Hua, and Zhengdong Cai

Subjects
Osteosarcoma, CYT997, ER stress, ROS, ERO1A, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Osteosarcoma (OS) is a common malignant cancer in children and adolescents and has a cure rate that has not improved in the last two decades. CYT997 (lexibulin) is a novel potent microtubule-targeting agent with various anticancer activities, such as proliferation inhibition, vascular disruption, and cell cycle arrest and apoptosis induction, in multiple cancers. However, the direct cytotoxic mechanisms of CYT997 have not yet been fully characterized. Methods We evaluated apoptosis and autophagy in human osteosarcomas after treatment with CYT997 and investigated the underlying mechanisms. To explore relationships, we used the reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC), PERK inhibitor GSK2606414, ERO1 inhibitor EN460 and mitochondrial targeted protection peptide elamipretide. BALB/c-nu mice were inoculated with 143B tumor cells to investigate the in vivo effect of CYT997. Results We explored the efficacy and mechanism of CYT997 in osteosarcoma (OS) in vitro and in vivo and demonstrated that CYT997 potently suppresses cell viability and induces apoptosis and autophagy. CYT997 triggered production of ROS and exerted lethal effects via endoplasmic reticulum (ER) stress in OS cells. NAC attenuated these effects. The PERK inhibitor GSK2606414, which can block the ER stress pathway, reduced ROS production and enhanced cell viability. Moreover, activation of ERO1 in the ER stress pathway was responsible for inducing ROS production. ROS produced by the mitochondrial pathway also aggravate ER stress. Protection of mitochondria can reduce apoptosis and autophagy. Finally, CYT997 prominently reduced tumor growth in vivo. Conclusions This study suggests that CYT997 induces apoptosis and autophagy in OS cells by triggering mutually enhanced ER stress and ROS and may thus be a promising agent against OS.

Published
2019
Full Text
View/download PDF

31. Treatment for Retinopathy of Prematurity in Twins: The Small Twin without High Birth Weight Discordant Is Not at Increased Risk

Author

Enzhong Jin, Zongyi Wang, Lu Yao, Hong Yin, and Mingwei Zhao

Subjects
retinopathy of prematurity, twins, risk factors, low birth weight, treatment, Pediatrics, RJ1-570
Abstract

Purpose: As common retinopathy is observed in low-birth infants, the characteristics of ROP in twins are worth exploring. The present study tried to demonstrate the risk factors of treatment for retinopathy of prematurity (ROP) in twins both diagnosed with ROP. Methods: A retrospective, institution-based cohort study of 62 premature ROP twin pairs with a mean gestational age (GA) younger than 35 weeks and a birth weight (BW) lower than 2500 g. Only infants with a follow-up period longer than 6 months and complete treatment records were included. The demographic data, treatment requirements and further rescue treatments were all collected and analyzed for all infants according to whether they accepted treatments. Moreover, all twin infants were divided into small and large twin groups according to birth weight, and they were also categorized as three groups according to the treatment requirement including both twins receiving treatment (BT group), one of the twins receiving treatment (ST group) and none of the twins receiving treatment (NT group). Comparisons of demographic data, treatment requirements and further rescue treatments were all conducted according to the different grouping methods. Results: The mean GA of the enrolled infants was (29.29 ± 2.45) weeks with a mean BW of (1335.77 ± 390.36) grams. Among them, 110 infants were mechanically ventilated. Fifty-one of the infants did not receive any treatment and 73 infants received laser or intravitreal injection of anti-VEGF agents. In total, 64 infants only underwent intravitreal injection of anti-VEGF agents or laser treatment, while the other nine infants received scleral buckling or vitrectomy as a necessary treatment when the retinal detachment was observed. No significantly different mechanical ventilation or treatment requirements could be observed between the small twin group and the large twin group (p = 0.73, 0.94). The twins in the BT groups showed the lowest BW, while the NT group infants had the highest BW. The GA for the BT, ST and NT groups were (27.86 ± 1.87) weeks, (29.60 ± 1.52) weeks and (31.33 ± 2.39) weeks, respectively, and showed significant differences as well (p < 0.001). Conclusion: Being a small twin in twin-paired ROP without a high BW discordant will not increase the risk for treatment requirement or additional surgery necessity with a much more severe stage of ROP.

Published
2022
Full Text
View/download PDF

32. Is vitamin K a treatment choice for atypical femoral fractures in patients with secondary osteoporosis?

Author

Bingzhang Wang, Jiahao Tang, Sheji Weng, Liang Chen, Zongyi Wu, Zhongjie Xie, and Lei Yang

Subjects
Medicine (General), R5-920
Abstract

An atypical femoral fracture (AFF) is a rare complication associated with excessive inhibition of osteoclast expression during treatment of osteoporosis. We herein describe a patient who had been treated with alendronate for more than 10 years and subsequently developed an AFF that healed after treatment with vitamin K 2 (VK2). We also discuss the potential beneficial effects of VK2 on the healing of AFFs. A 48-year-old Asian man with secondary osteoporosis was treated with alendronate for more than 10 years. The patient underwent surgical treatment for a complete AFF of the right femur. Six months postoperatively, he complained of pain in his left thigh. X-ray examination revealed an incomplete AFF of the left femoral shaft. He was then treated with VK2. After 4 months of VK2 treatment, the patient reported that the pain in his left thigh had decreased, and follow-up X-ray examination demonstrated healing of the left AFF line. This case report indicates that VK2 may be a potential direction for pharmacological treatment of AFFs in future research.

Published
2021
Full Text
View/download PDF

33. The Isolation and Molecular Characterization of an Astrovirus From 'Yellow' Chickens, China

Author

Wei Zhao, Zongyi Wu, Yongxiu Yao, Aijian Qin, and Kun Qian

Subjects
astrovirus, chicken, isolation, sequence analysis, molecular characterization, Veterinary medicine, SF600-1100
Abstract

Chicken astrovirus (CAstV) infection is strongly associated with kidney disease, gout, “white chicks” hatchery disease, and runting and stunting syndrome (RSS). In the present study, 82.5% of 154 clinical samples from different provinces in China were positive for CAstV by RT-PCR. One CAstV isolate, designated as AAstV/Chicken/CHN/2017/NJ01, was successfully isolated from the small intestine of “Yellow” chickens using LMH cells. The genome sequence and structure analyses revealed that NJ1701 had the typical characteristics of avian astroviruses which was genetically distinct from other Avastrovirus. This isolate was classified as Group B subgroup i based on phylogenetic analysis of complete ORF2 (capsid) amino acid sequences. Meanwhile, growth depression and hatchability reduction were observed in the chicken embryo infection experiment. The results in the current study will contribute to our understanding of chicken astrovirus in China.

Published
2020
Full Text
View/download PDF

34. Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration

Author

Zongyi Wang, Mengyang Li, Yuou Yao, Jie Hu, Jiyang Tang, Ran Tang, Zhenyu Piao, and Jinfeng Qu

Subjects
Ophthalmology, RE1-994
Abstract

Purpose. To study the short-term anatomical and functional outcomes in patients with neovascular age-related macular degeneration (nAMD) who were previously treated with conbercept and switched to ranibizumab or bevacizumab due to persistent activity. Methods. This retrospective single-arm study included nAMD patients who were followed up for at least three months after switching from at least 3 monthly intravitreal conbercept injections to bevacizumab or ranibizumab for persistent choroidal neovascularization (CNV) activity. The demographic data, treatments, best-corrected visual acuity (BCVA), central macular thickness (CMT), and the height of pigmented epithelial detachment (PED) before and after switching were recorded and analyzed. Results. A total of 64 eyes of 64 patients were included with a mean follow-up of 9.6 ± 3.0 months. The average number of injections of conbercept was 3.6 ± 0.8 (range, 3–5) before switching. 18 eyes were switched to bevacizumab, and the other 46 eyes were switched to ranibizumab. After switching, mean BCVA slowly improved from 0.73 ± 0.48 to 0.64 ± 0.41 (p=0.0132) at one month after the last intravitreal injection of ranibizumab or bevacizumab during the mean follow-up of 4.4 ± 2.0 months. One month after switching, the mean CMT decreased significantly from 294.9 ± 121.8 μm to 230.9 ± 107.0 μm (p

Published
2020
Full Text
View/download PDF

35. Administration of cinnamaldehyde promotes osteogenesis in ovariectomized rats and differentiation of osteoblast in vitro

Author

Zongyi Wu, Sheji Weng, Deyi Yan, Zhongjie Xie, Qiang Zhou, Hang Li, Bingli Bai, Viraj Boodhun, Zijian Shen, Jiahao Tang, Lingling Zhou, Zhoushan Tao, and Lei Yang

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

To explore the effect of cinnamaldehyde on the distal femur in ovariectomized rats and its influence on osteoblast in vitro. Female Sprague–Dawley rats which underwent either bilateral ovariectomy or sham operation were divided into five groups randomly: group OVX (OVX, N = 10) and group sham (SHAM, N = 10) received normal saline (NS) by gavage at a dose of 50 ml/kg·d; group low dose, group middle dose and group high dose received cinnamaldehyde by gavage at a dose of 25 mg/kg·d (OLD, N = 10), 50 mg/kg·d (OMD, N = 10), and 75 mg/kg·d (OHD, N = 10) respectively. Distal femurs were harvested for hematoxylin and eosin (HE) staining, micro-ct scanning and immunohistochemical analysis. Murine mesenchymal stem cells were cultured and dealt with the presence of either cinnamaldehyde at a dose of 15ug/ml (OLD), 30ug/ml (OMD), 60ug/ml (OHD) or vehicle. ALP staining and western blot were performed to observe the influence of cinnamaldehyde on the differentiation of osteoblast. HE and micro-ct results indicated that osteogenesis were promoted with the treatment of cinnamaldehyde. Immunohistochemical results showed that cinnamaldehyde increased the number of osteoblast and decreased the number of osteoclast. In vitro studies indicated that cinnamaldehyde promoted expression of alkaline phosphatase (ALP), runt-related transcription factor 2 (RUNX2), osteocalcin (OCN) and collagen type Iɑ1 (COL1ɑ1). The treatment effect behaved as dose-dependently. Thus, cinnamaldehyde inhibits osteoclastogenesis and promotes osteoblastogenesis, and may plays an important role in the treatment of osteoporosis clinically. Keywords: Cinnamaldehyde, Anti-Osteoporosis, Bone morphology, Osteoblast, Osteoclast

Published
2018
Full Text
View/download PDF

36. The Bacterial Effector AvrB-Induced RIN4 Hyperphosphorylation Is Mediated by a Receptor-Like Cytoplasmic Kinase Complex in Arabidopsis

Author

Ning Xu, Xuming Luo, Wen Li, Zongyi Wang, and Jun Liu

Subjects
Microbiology, QR1-502, Botany, QK1-989
Abstract

Bacterial pathogen Pseudomonas syringae delivers diverse type III effectors into host cells to interfere with their immune responses. One of the effectors, AvrB, targets a host guardee protein RIN4 and induces RIN4 phosphorylation in Arabidopsis. Phosphorylated RIN4 activates the immune receptor RPM1 to mount defense. AvrB-induced RIN4 phosphorylation depends on RIPK, a receptor-like cytoplasmic kinase (RLCK). In this study, we found several other RLCKs that were also able to phosphorylate RIN4. We demonstrated that these RLCKs formed a complex with RIPK and were functionally redundant to RIPK. We also found that unphosphorylated RIN4 was epistatic to phosphorylated RIN4 in terms of RPM1 activation. AvrB-induced RLCK gene expression and phosphorylated RIN4–triggered RPM1 activation required RAR1, a central regulator in plant innate immunity. Our results unravel a mechanism in which plants employ multiple kinases to hyperphosphorylate the guardee protein RIN4 to ensure immune activation during pathogen invasion.

Published
2017
Full Text
View/download PDF

37. The fast degradation of β-TCP ceramics facilitates healing of bone defects by the combination of BMP-2 and Teriparatide

Author

Zhongjie Xie, Deyi Yan, Qiang Zhou, Zongyi Wu, Sheji Weng, Viraj Boodhun, Bingli Bai, Zijian Shen, Jiahao Tang, Liang Chen, Bingzhang Wang, and Lei Yang

Subjects
Osteoporosis, Bone defect, BMP, Teriparatide, β-TCP, Degradation, Therapeutics. Pharmacology, RM1-950
Abstract

Accumulating evidence suggests that the degradation and resorption of calcium phosphate ceramics is always relatively slow, which may inhibit calcium phosphate ceramics’ replacement by new bone tissues and the ultimate bone defect repair. Bone morphogenetic proteins (BMPs) and Teriparatide (PTH) are extensively applied in the treatment of bone pathologies, while their effects on the degradation of calcium phosphate ceramics is limited. In this study, we tested the effects of BMP and PTH on degradation of β-tricalcium phosphate (β-TCP) ceramics and bone formation on β-TCP in ovariectomized (OVX) rat models. After establishment of femur defect model on OVX rats, the BMP + PTH group’s rats were injected Teriparatide (30 μg/kg) subcutaneous every other day, while rats of control group and group BMP were injected equal-to-group volume sterilized saline water. Twelve weeks after femur surgery, all rats were sacrificed for Micro-CT scanning and histology tests. The results showed that BMP facilitated degradation of β-TCP and new bone formation on β-TCP ceramics. And PTH showed an additional effect on degradation of β-TCP when combined with BMP. In addition, the results explained that PTH promoted the remodeling of the bone callus occurred during repair.

Published
2019
Full Text
View/download PDF

38. Performance Status Evaluation of an Electric Vehicle Charging Infrastructure Based on the Fuzzy Comprehensive Evaluation Method

Author

Qiushuo Li, Yong Xiao, Shuaishuai Zhao, Xianwen Zhu, Zongyi Wang, Zisheng Liu, Ling Wang, Xiangwu Yan, and Yan Wang

Subjects
electric vehicle charging infrastructure, fuzzy comprehensive evaluation, performance evaluation, Electrical engineering. Electronics. Nuclear engineering, TK1-9971, Transportation engineering, TA1001-1280
Abstract

Performance status evaluation is essential for the safe running of electric vehicle (EV) charging infrastructure. With the development of the EV industry, the EV charging infrastructure industry has advanced considerably. Safe and reliable operation of the charging infrastructure is important for the development of EVs. As such, we propose a comprehensive evaluation method to assess the performance condition of an EV charging infrastructure. First, based on the analysis of the existing EV charging principles, we established an evaluation index system for EV charging infrastructure. Second, the subjective weight, objective weight, and comprehensive weight of the index system were determined through analytic hierarchy processes (AHP) and the entropy weight method. Then, we used fuzzy comprehensive evaluation to appraise the performance of the charging infrastructure through expert investigation. Finally, based on the actual data from an EV charger, the performance conditions of the EV charging infrastructure were evaluated to demonstrate the feasibility of the method and the reliability of the index system.

Published
2019
Full Text
View/download PDF

39. Traveling waves and spreading speed on a lattice model with age structure

Author

Zongyi Wang

Subjects
Lattice differential system, spreading speed, traveling wave, minimal wave speed, Mathematics, QA1-939
Abstract

In this article, we study a lattice differential model for a single species with distributed age-structure in an infinite patchy environment. Using method of approaches by Diekmann and Thieme, we develop a comparison principle and construct a suitable sub-solution to the given model, and show that there exists a spreading speed of the system which in fact coincides with the minimal wave speed.

Published
2012

40. Directed elimination of senescent cells attenuates development of osteoarthritis by inhibition of c-IAP and XIAP.

Author

Peilin W, Songsong T, Chengyu Z, Zhi C, Chunhui M, Yinxian Y, Lei Z, Min M, Zongyi W, Mengkai Y, Jing X, Tao Z, Zhuoying W, Fei Y, and Chengqing Y

Subjects
Animals, Apoptosis, Autophagosomes, Autophagy, Azocines antagonists & inhibitors, Benzhydryl Compounds antagonists & inhibitors, Cell Cycle, Cell Proliferation, Disease Models, Animal, Gene Expression Regulation, Inhibitor of Apoptosis Proteins genetics, Lysosomes, Osteoarthritis pathology, Qa-SNARE Proteins metabolism, Rats, Rats, Sprague-Dawley, Risk Factors, Cellular Senescence physiology, Inhibitor of Apoptosis Proteins metabolism, Osteoarthritis metabolism
Abstract

Aging drives the accumulation of senescent cells (SnCs) by secreting factors that cause the senescence-associated secretory phenotype (SASP), including stem cells in the bone marrow, which contribute to aging-related bone degradation. Osteoarthritis (OA) is a serious chronic injury disease, and increasing age is a major risk factor. The accumulation of SnCs may accelerate the development of OA, and the accumulation of SnCs may benefit from its resistance to apoptotic stimuli. Therefore, local elimination of SnCs could be a promising treatment for OA. Apoptosis inhibitor protein (IAP) is an important antiapoptotic protein in vivo. AT-406 is a small molecule inhibitor of the IAP genes and also regulates the transcription of several genes. Here, we show that SnCs upregulate the antiapoptotic proteins c-IAP1, c-IAP2 and XIAP.The combined inhibition of c-IAP1, c-IAP2 and XIAP using siRNA or AT-406 specifically induce the apoptosis of SnCs.In addition, XIAP and STX17 bind to each other to regulate the fusion of autophagosomes and lysosomes in SnCs, which in turn, affects the fate of SnCs. It is worth noting that the clearance of SnCs attenuated the secretion of SASP and created a proregenerative environment. Most importantly, local clearance of SnCs significantly attenuated the progression of osteoarthritis in rats without significant toxic effects. Thus, local elimination of SnCs may be a potential treatment for OA. This is the first report of inhibition of IAPs for clearing SnCs and suggests that eradication of SnCs may be a new strategy for the treatment of age-related diseases., (Copyright © 2019 Elsevier B.V. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results